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Journalistic Framing of the Food and Drug Administration: How Do Our Nation’s Most 




  The Food and Drug Administration is committed to serving the public interest by 
approving drugs that have to be both safe and effective.  Yet, the FDA is not just doing its job in 
a vacuum.  Due to the nature of food and drug issues and their important implications for health, 
every FDA decision is put under intense scrutiny by the political figures in government, 
pharmaceutical and public interest groups, and, finally, by the consumers themselves.   
  This paper explores how the FDA is represented in three major newspapers across the 
country.  The aim of the paper is to discern whether any of the newspapers show a bias towards 
the FDA through negative or positive reporting and, similarly, whether some discrepancies 
among the newspapers might be explained by liberal or conservative tendencies.  The paper 
begins with an overview of framing within the news media, explaining just how important news 
reporting can be for public perception of the FDA.  It then addresses research methodology and 
research questions.  Next, it analyzes, in detail, the newspaper reporting styles and possible bias 
of each newspaper individually.  It concludes with a comparison of the three newspapers by 
testing this analysis against the original hypothesis and offering possible explanations for 
discrepancies.   
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I. Introduction 
 
A. Media Framing 
   
The media permeates almost every aspect of American society and serves as the arm of 
communication between the mass public and government action.  As a result, the journalistic 
community occupies a powerful position of persuasion.  News organizations have the 
opportunity to shape how the public will perceive an issue.  They can do this through a variety of 
framing techniques and story choices.  For example, whether a newspaper chooses a negative or 
positive quote and what part of a story it chooses to highlight in each article can influence what a 
reader pays attention to or remembers.  Not surprisingly, much research (particularly in the field 
of political science) attempts to learn a little bit about how the media uses this great power.  Yet, 
framing is not a concept that is unique to media reporting.  Politicians constantly try to shape the 
message they send to constituents through carefully orchestrated appearances and speeches.  
Interest groups frame an issue differently depending on who they are trying to reach.  Most 
framing in our society occurs deliberately, with a person or organization trying to color a 
particular story or create a particular impression.  Contrarily, newspapers are supposed to be 
objective and any editor will likely claim that it is, albeit sometimes admitting that the newspaper 
leans in one political direction or another.  
Some past studies help to emphasize the importance of framing techniques and highlight 
the difference between deliberate framing and unintentional framing.  Much of the framing 
literature concentrates on how an interest group frames its own cause in the general public.  
Framing can be used for specific reasons: “to attract new recruits, sustain the morale and 
commitment of current adherent, generate media coverage, mobilize the support of various 
bystander publics, constrain the social control options of its opponents, and shape public 4 
policy.”
1  Framing can be both positive and negative and can influence the public in different, 
intentional ways.  For example, in the civil rights movement, “[Martin Luther] King succeeded 
in grounding the movement in two of the ideational bedrocks of American culture [by] applying 
Christian themes and conventional democratic theory.”
2  Many credit his success to his 
nonviolent approach that focused on the positive frames of rights and religion.  On the other 
hand, negative frames can be used to describe the opposition position without directly naming 
that group.  For example, “affirmative action has been framed variously as ‘remedial action’ for 
the continuing affects of discrimination or ‘reverse discrimination’ against whites and/or 
males…[and] welfare has been framed as ‘a helping hand’…and as a ‘government handout’.”
3   
  Every interest group, political figure, or government organization like the Food and Drug 
Administration (FDA) will naturally have its critics.  This is especially true for interest groups 
and social movements.
4   With two movements fighting about the same issue, interaction is 
inevitable and undoubtedly will influence the prospects of success.  For example, the Roe v. 
Wade decision was the main catalyst for the emergence of a strong right to life movement in 
American society.
5  Laura Woliver study on amicus briefs found that “after the Roe victory, the 
pro-choice movement’s agenda was partially shaped by having to respond to the burgeoning pro-
life countermovement.”
6   
Related to the FDA, a similar phenomenon is seen in politics and in reporting on 
government organizations or agencies where two different value-focused groups exist: liberal 
                                                 
1 Doug McAdam, The Framing Function of Movement Tactics: Strategic Dramaturgy in the American Civil Rights 
Movement, in COMPARATIVE PERSPECTIVES ON SOCIAL MOVEMENTS 340 (Doug McAdam, John D. McCarthy, and 
Mayer N Zald, eds., 1996). 
2 Doug McAdam, 347. 
3 Thomas E. Nelson and Zoe M. Oxley, Issue Framing Effects on Belief Importance and Opinion, THE JOURNAL OF 
POLITICS, Nov. 1999, http://www.jstor.org/. 
4 Id. 
5 Kristin Luker, Abortion and the Politics of Motherhood  142 (1984). 
6 Laura Woliver, Social Movements and Abortion Law, in SOCIAL MOVEMENTS AND AMERICAN POLITICAL 
INSTITUTIONS 234 (Anne N. Costain and Andrew S. McFarland eds., 1998). 5 
and conservatives.  Therefore, framing can effect how the public perceives the government, a 
particular figure, or an important agency.  An article that is con-FDA might positively frame the 
critics or, on the contrary, ignore the FDA’s position all together.  This can occur even 
unintentionally, as when an article just reports on a negative development without considering 
positive implications or defenses.  In fact, many critics argue that the media is consistently guilty 
of ignoring the positive and focusing on the negative to sell a story.  For example, Britney 
Spears’ escapades as a “bad mother” rarely depict the times when she is serving as a positive role 
model for the children.  Even if the story is true, there is no escaping the fact that the magazines 
are choosing to focus on the negative tabloid stories, even if the positive omissions are not 
deliberate.    
Newspapers are most often studied for their framing techniques in relationship to political 
campaigning.  Newspapers are constantly criticized for getting caught up in the “horse race” 
rather than taking the time to report on the important issues in the campaign.  One well respected 
political scientist, Thomas Patterson, defines horse race coverage as “the dominant schema for 
the reporter is structured around the notion that politics is a strategic game.”
7   Patterson 
continues that “the press does in fact communicate a lot of substance during the campaign, but 
the focus of news buries much of it and distorts much of the rest.”
8  One study by Kathleen 
Jamieson and Paul Walden say that in “the last . . . Presidential elections . . . 71% of stories in 
2000 were primarily concerned with the “horse race” as opposed to issues, compared to 48% in 
1996 and 58% in both 1992 and 1988.”
9  The overall trend in reporting is to focus on the part 
that will sell.  In a similar way, it should be interesting to see if the newspapers also tend to focus 
on the negative story or only one side of the argument in general reporting on the FDA.   
                                                 
7 Thomas Patterson, Out Of Order 57 (1993). 
8 Thomas Patterson, 60. 
9 Kathleen Hall Jamieson and Paul Waldman, The Press Effect 168 (2003). 6 
B. Background on Topics, Vioxx, Plan B, Ephedra 
1. Vioxx 
In order to understand how an article is actually depicting the FDA, it is important to give 
a very brief introduction to each of the topics.  The first topic is the Vioxx controversy 
surrounding pharmaceutical giant Merck and the FDA.  Vioxx became one of Merck’s largest 
and most successful drugs after its 1999 FDA approval and release.
10  Vioxx is a Cox-2 inhibitor 
drug meant to relieve certain types of pain such as arthritis.
11  Only 11 days after its release, it 
was distributed to over 30,000 pharmacies to administer to over 40 million potential arthritis 
patients.  One commentator explains the benefits of the drug:  
“Vioxx, along with other cox-2 inhibitors, work[s] by isolating and 
inhibiting the cox-2 enzymes in the body. Standard non-steroid anti-
inflammatory drugs [a]re unable to do this without also affecting the 
cox-1 enzyme, which is essential to the body’s gastric health. As a 
result standard drugs [a]re the cause of a variety of gastric and health 
problems, whereas cox-2 inhibitors [a]re hailed miracle drugs...”
12 
Yet, around 2004, issues started surfacing about potential serious side effects based on 
drug tests.  Most seriously, the drug was found to significantly increase the risk of heart attacks 
and strokes.  There was a huge public outcry over this revelation and in September 2004, Merck 
decided to voluntarily withdraw the drug from the market place.  The FDA was pulled into the 
controversy when critics began arguing that the drug should never have been approved at all.  
Merck is and has been involved in various lawsuits, especially since internal documents reveal 
                                                 
10 Vioxx Legal Help, http://www.vioxxandcelebrexlegalhelp.com/. 
11 Thefreedictionary.com, Vioxx, http://www.thefreedictionary.com/Vioxx 
12 Lawcore.com, Vioxx Recall, http://www.lawcore.com/vioxx/vioxx-recall.html (last visited Jul. 19, 2007). 7 
that the company knew about the side effects before the drug was marketed.  Thus, the Vioxx 
controversy represents a particularly negative story with respect to the FDA. 
2. Plan B 
The second research topic focuses on Plan B, a morning-after pill, and the controversy 
that surrounded over-the-counter approval.  Pharmaceutical companies, such as Barr 
Pharmaceuticals, applied to the FDA to allow Plan B to be sold over-the-counter (i.e. without a 
prescription).
13  In early 2004, the FDA’s Center for Drug Evaluation and Research rejected this 
application.  The FDA cited “concern that not enough was known about the possible effects of 
the pills on the sexual activity of young girls.”
14   
Yet, the staff scientists at the FDA and other outside panels recommended approval.  
Public criticism followed.  For example, Mark McClellan, the former FDA commissioner, 
argued that the new acting Director, Steve Galson, was not using the same standards for Plan B 
that the FDA has used for other contraceptive drugs.
15  Critics argued that the FDA ignored the 
science based decision making process in favor of a more ideological stance focused on age 
related restrictions.
16  In fact, some interest groups, such as the Center for Reproductive Rights, 
filed a lawsuit against the FDA based on this approval process.
17  At the same time, supporters of 
the FDA argued that the FDA was looking out for young women and it was better to be cautious 
in these matters.
18  However, the FDA eventually approved Plan B for over-the-counter sales for 
women over age 16 in 2006.   
3. Ephedra 
                                                 
13 Media Matters for America, ABC's "Closer Look" at Plan B Controversy Aired Conservatives' Safety Concerns, 
Ignored FDA scientists' Rejection of Them, May 10, 2006, http://mediamatters.org/items/200605100014. 
14 Vicki Kemper, FDA Chief Says He Made Morning After Pill Decision, L.A. TIMES, May 8, 2004. 
15 Id.  
16 Leila Abboud, FDA Restricts Morning After Pill, WALL ST. J., May 7, 2004. 
17 Wikipedia.com, Emergency Contraceptive, http://en.wikipedia.org/wiki/Emergency_contraception (last visited 
Jul. 21, 2007). 
18 Editorial, What Do Women Want? A Pill or Much More, N.Y. TIMES, May 12, 2005. 8 
  The final research topic deals with the Ephedra controversy.  This is particularly 
interesting given the regulatory issues surrounding the FDA’s actual power to control dietary 
supplements.  Ephedra is the main ingredient in some popular weight loss products.
19  The FDA 
has constantly worried about reports of adverse effects.  As early as 1997, the FDA proposed a 
limit on the drug’s use.  However, it was forced to withdraw that proposed rule after government 
investigators concluded that the FDA did not have a sound scientific support base.
20  As a result, 
the FDA initially failed to find a solution.   
  In 2002 and early 2003, the FDA beefed up efforts to attack Ephedra.  These years tend 
to be the focal point of most media reports.  Finally, in December 2003, the FDA announced 
plans to ban dietary supplements containing Ephedra due to health concerns.
21  Interestingly, 
CNN reports that this was the first time that the FDA used its powers to block sale of an over-
the-counter nutritional supplement.  Pre-1994 (old) dietary supplements do not have to be proven 
safe before going to the market, unlike drugs.  However, the FDA is able to act if an old dietary 
supplement is later found to be unsafe.
22  Even though the FDA ended up succeeding in 
removing the product from the market, many public figures felt that the FDA did not act quickly 
or fervently enough on this issue in the late 1990s.  Others defended the FDA, arguing that 
regulatory restraints and public apathy made any potential ban difficult.  The Ephedra 
controversy is the least critical of the FDA out of all three topics, but still represents an overall 
negative event. 
 
                                                 
19 http://www.supplementquality.com/news/ephedra_controversy.html 
20 Id. 
21 Shari Roan, Many Fans of Herb Had Moved on to Newer Supplements, L.A. TIMES, Dec. 31, 2003. 
22 Government Announces Ban on Ephedra, CNN, Dec. 31, 2003, 
http://www.cnn.com/2003/HEALTH/12/30/ephedra/. 9 
II. Research Question 
  Unlike political candidates and interest groups, the FDA is an established part of the 
governmental apparatus.  It holds a distinguished place within the so-called fourth branch of 
government, the administrative state.   This study asks whether the nation’s most respected 
newspapers focus on the negative stories or frame the FDA negatively in the news media similar 
to how magazines frame famous celebrities.  It focuses on whether a newspaper’s reputation for 
being liberal or conservative comes into play in its FDA reports.  Specifically, it aims to study 
the impression the American public gets from the news media, its main source of information, 
about the FDA and the job the FDA is doing in protecting the public.  Does the news media feel 
that the FDA is accomplishing its task of protecting the public?  Is it framing the FDA as being 
aggressive or passive in its approach to unforeseen problems?  Does it exemplify certain bias that 
might be considered more liberal or conservative approaches to the FDA within the political 
ideological spectrum?  
  This coded research study is divided into two main parts that are designed to address four 
specific questions: 
1)  How do three of the nation’s most respected newspapers, the New York Times, the Los 
Angeles Times, and the Wall Street Journal, choose to report on the FDA?  This section 
does not compare the newspapers with each other, but rather talks about each 
newspaper’s individual results.  
a.  Does the newspaper focus on more positive framing or more negative framing? 
b.  Does the newspaper include both sides, including the FDA's position?  
c.  Do the editorials tend to focus on a specific type of criticism? 
d.  Does the newspaper demonstrate a liberal or conservative bias? 10 
2)  When comparing the newspapers with each other, is the framing technique consistent or 
does one newspaper tend to: 
a.  Publish more negative, positive, or neutral stories overall? 
b.  Give a more balanced approach, allowing both sides to be heard, or focus on 
negative criticism? 
c.  Show a propensity for one type of critique (overly cautious vs. too quick to 
approve drugs) over a more neutral approach? 
i.  Editorial Focus. 
ii.  Liberal/Conservative Issue Focus. 
 
III. Newspapers and Topics Chosen 
The three newspapers chosen serve as the study’s examples of the print media: the New 
York Times, the Los Angeles Times, and the Wall Street Journal.  These newspapers are selected 
for specific reasons.  First, the newspapers are read by a large percentage of the American 
populace.  If the study uses a small, local newspaper, it could not be clear whether it has enough 
readership to influence any public perception.  Second, each newspaper serves a different subset 
of the American population: New York, California, and Washington D.C.  Focusing on 
newspapers across the United States rather than in one defined geographical area recognizes that 
reporting techniques might differ within such a wide, diverse country.  However, due to this 
difference, it is possible that some results might be caused by the importance of the subject 
matter to a particular region more than an approach towards the FDA.  Finally, each newspaper 
has its own political reputation.  While all three newspapers have an unparalleled reputation in 
American society and the world for quality reporting, they also have a conservative or liberal 11 
reputation since that is a major part of this study.  The Los Angeles Times has a very strong 
liberal reputation.  At the other end of the spectrum is the Wall Street Journal with a reputation 
for conservative values, albeit usually seen more in the editorial section than in the regular news 
reporting section.  The newspaper is marketed to the business community, which has a known 
reputation for being more conservative.  The newspaper might react more positively to the FDA 
so as not to burn bridges with a powerful agency.  Finally, the New York Times also has a strong 
liberal reputation, but perhaps slightly less liberal than the Los Angeles Times.  
  The study focuses on three major stories (Vioxx, Plan B, and Ephedra) that touch on the 
FDA’s role as the arbiter of the American public’s safety in relationship to the food and drug 
industry.  Like the newspapers, these three topics are chosen for very specific, important reasons.  
First, all three topics are overall negative stories.  It is rarer for a newspaper organization to 
report about the FDA for an extended period of time when it is only a positive story.  To get a 
significant amount of articles for each topic so that the percentage breakdowns and qualitative 
analyses have any value, the topics need to remain in the media for a significant amount of time.  
Note that the topic is “negative” in the sense that the story is negative, and not necessarily that 
the FDA’s role in the story is negative.
23   
Second, the topics should bring out some liberal or conservative biases within the 
reporting and framing used by the outlets.  This is slightly harder to analyze because the coding 
must be based on the author’s personal judgment of liberal or conservative viewpoints from a 
political science background and some help from an article when it quotes a conservative group 
or labels a viewpoint as liberal.  Since newspapers are supposed to be objective, it should be 
                                                 
23 For example, the stories vary greatly in terms of how negative they are toward the FDA.  Ephedra is actually a 
more positive story about the FDA as compared to Vioxx where the FDA really was placed in a position of blame.  
Having different degrees of negativity will allow the results to take into consideration the tone of the story so as not 
to confuse it with the bias of the newspaper towards the FDA.  12 
particularly interesting to see if the newspapers with a liberal or conservative reputation 
demonstrate this reputation in its reporting about what is supposed to be a neutral agency, the 
FDA, rather than a more clearly political topic such as an election horse race.  As such, topics 
that lend themselves to conservative or liberal values are crucial.
24  Finally, for a similar control 
reason, the topics all occur within the last six years, during the Bush Administration.  Since a big 
part of the study is the liberal or conservative tendency of a newspaper, it makes sense to keep 
the time-span all within one Administration.  In addition, the results should be as current as 
possible.  Reporting techniques from ten years ago might not be relevant to the reporting 
techniques of these newspapers today. 
 
IV. Methodology 
  The paper is divided into two main sections.  The first section focuses on the individual 
newspapers.  Topic A studies the New York Times for all four research questions listed above.  
Within topic A are three subsections: a section on Vioxx, Plan B, and Ephedra.  Another 
alternative would have been to study all the papers under Vioxx, then under Plan B, and then 
under Ephedra.  However, since this part is not meant to be a comparison among the newspapers, 
but rather an individual study of each newspaper and the different reporting styles used within 
the topics, the first arrangement makes more sense.  Hence, topic B focuses on the Los Angeles 
Times, and topic C focuses on the Wall Street Journal.  Within each subsection, there is a 
quantitative graphical study and a qualitative study of the results.  The qualitative study talks 
generally about the results, gives article examples, and finally discusses why certain patterns or 
trends might exist.  When relevant, any interesting framing techniques are highlighted.  The 
                                                 
24 As one will see in the analysis section, the Ephedra topic is the weakest here since there are not very clear 
conservative and liberal divides on the issue whereas the Plan B topic has a more clear divide.   13 
quantitative section looks at the actual statistical data within each newspaper’s reporting.  This 
quantitative and qualitative approach is repeated for all four research questions within Part I: (1) 
the negative, positive, or neutral coverage breakdown, (2) the balanced or one-sided reporting, 
(3) the editorial breakdown, and (4) the liberal/conservative breakdown.  The editorial section is 
specifically chosen because it is the only time the newspaper can choose to be subjective and so 
it might be the best indicator of a newspaper’s bias or values.  Even when the overall results 
might appear to be neutral, the editorials might uncover a more negative or positive reporting 
style.     
The second section of the study compares the three newspapers quantitatively with a 
qualitative analysis and discussion of the results.  The same four topics from the first section are 
used here, but this time they are employed to compare the newspapers.  The results from the first 
section are the underlying data for this section.  Does one newspaper tend to be more negative?  
Even if all are negative, if one newspaper is significantly less negative than the others, it might 
actually represent a more positive FDA coverage than it appeared to be as an individual study.  
The coding for these articles is quite subjective, based on a personal evaluation about 
what falls into each category.  Each article is read in detail and coded for overall negativity, any 
positive or neutral comments, and any liberal or conservative topics.  Similarly, each article is 
labeled as negative, negative/neutral, neutral, positive/neutral, or positive.  To be consistent 
throughout the differing newspapers, each evaluation uses the same coding criteria per topic for 
each newspaper.  All articles are printed and highlighted for all positive and negative quotes 
about the FDA in different colors.  In order to notice some possible framing techniques, negative 
quotes from community figures are highlighted in a different color than negative sentences 
written by the newspaper author.   14 
To perform the search, FDA or F.D.A or Food /2 Drug were typed in, followed by the 
name of the topic.  For example, for Plan B the search was Plan B or morning /2 after or 
contraceptive AND FDA or F.D.A or Food /2 Drug.  The study focuses on a period of around 2-
3 years based on when the topic should be most in the news.  Using this technique, all articles 
were printed, ranging from a maximum of 500 articles for Vioxx reporting in the New York 
Times to a much smaller number for Ephedra.  Then each article was read, with about 50% being 
discarded per topic per newspaper when the article really had absolutely nothing to do with the 
FDA or the topic, but just happened to have all the key terms in various places.  For example, 
many times in a three page article the only reference to Vioxx is that this particular company also 
made Vioxx.  Accordingly, the amount of coverage that is actually coded and included in the 
study varied from around 15 articles to almost 100 articles depending on the topic and the 
newspaper.   
To make the coding as unbiased as possible, a reliability test was performed using 15 
volunteers to code 9 articles (all within Vioxx and three for each newspaper) chosen at random to 
test the compatibility between the author’s coding and the volunteers’ coding.  The volunteers 
coded the articles based on a prepared check list with three of the research questions.  The 
editorial question was not included in the check list since it is not relevant to reliability (as the 
study does not differentiate between editorials and other articles when first coding for 
negativity).  The only difference from the check list and the research questions used is that for 
the liberal and conservative topic, the check list referred to “issues” rather than political bias so 
that the volunteers did not know that this is the aim of that question.  Also, they did not know the 
coding topics for positive, positive/neutral, negative, negative/neutral, or negative coverage.  For 
example, in the actual coding an article is positive whenever it blames someone other than the 15 
FDA.  The volunteers were not given this information, but only told to make their own judgment 
call.  Although 9 articles and 15 people are small numbers, it is difficult to find more people 
willing to do more articles for free.  However, for purposes of this paper, this should be 
sufficient.  
 Below are the results for one article.  A “1” represents negative and a “2” represents 
negative/neutral.
25  The actual coding of this particular article is negative, one-sided and liberal.  
As one can see, these results are comparable; with only a small percentage of volunteers thinking 
the article is neutral/negative rather than negative.  This reliability test results for the other 8 
articles are very similar with about 3-4 people on average choosing the next step up or down 
(i.e., negative/neutral to negative).  However, no graphically representation is included here to 
avoid repetitiveness.  There are a couple of occasions where a difference does occur, like with 
this example: some subjects found a conservative story in an article where none existed (where a 
“1” is liberal and a “2” is conservative topic).  Yet overall, the compatibility is strong enough 
that the results can be meaningful for this type of small scale study.  However, due to the 
difference, every section is broken down into two graphs: one that splits up the labels into 
positive, positive/neutral, neutral, negative, and negative/neutral and a second that combines 
negative/neutral with negatives and positive/neutral with positives (since this was most often the 
coding differences).  
                                                 
25 Note that the definitions used for coding of negative, negative/neutral, etc. will be explained in detail within the 
analysis section. 16 
  
V. Hypothesis 
  The study focuses on two major research topics: (1) an individual study of each 
newspaper and (2) a comparison of the newspapers.  The hypothesis for the first topic varies only 
slightly between two of the newspapers.  For the New York Times and the Los Angeles Times it is 
believed that both should have predominately negative portrayals of the FDA for all three topics.  
In addition, both newspapers should live up to their liberal reputation and report more liberal 
stereotypes and engage in more one-sided negative coverage.  Also, the editorials should focus 
more on negative stories.   These results should remain the same regardless of the topic.  
However, it is possible that the New York Times might print more neutral articles.  
  On the other hand, the Wall Street Journal results should be slightly different.  While it is 
predicted that there should be a similar negative slant for the Vioxx and Plan B stories, Ephedra 
might actually see more neutral reporting given that this story is more positive towards the 
FDA’s role overall.  The Wall Street Journal should also demonstrate a more conservative slant 
as compared to a liberal slant in its articles.   17 
  The second topic mirrors the predictions for the first topic.  It is predicted that there 
should be a sliding scale among the newspapers based on their reputation within each topic.  
Overall, the Los Angeles Times should be the most liberal, offering criticism that tends to 
represent liberal values.  The New York Times should be the most neutral, with more 
conservative articles than the Los Angeles Times but more liberal articles than the Wall Street 
Journal.   Finally, the Wall Street Journal should be the most conservative, tending to highlight 
conservative arguments in a much higher percentage than the other newspapers.   
Similarly, the Los Angeles Times should be the most one-sided, failing to highlight the 
FDA’s position.  At the same time, the Wall Street Journal should be more balanced in its FDA 
coverage than the New York Times.  This prediction is based on the fact that the current 
Administration is Republican and the Republican Party is stereotypically considered to be made 
up of the business community.  The Wall Street Journal arguably targets this ideological base.  
As a result, since the FDA might easily be seen as a part of the current government rather than a 
more independent agency, a more conservative Wall Street Journal might be more balanced 
within a negative story than the more liberal New York Times and the Los Angeles Times.  The 
Wall Street Journal might shy away from criticizing an agency that can have destabilizing effects 
on many big businesses.   
Yet note that these liberal and conservative labels are based mainly on reputation (as well 
as some studies).  Thus, it is equally possible that the reputations are inaccurate and the 
hypothesis should fail.  Also, the newspapers might not have any type of vendetta against the 
FDA, either intentional or not, and therefore there might be no patterns in the comparison at all 
and so any negative reporting on the FDA is due to the negative story rather than a particular bias 18 
against the Administration or the FDA.  It is only if there is a significant difference in the 
newspaper reporting styles that less than objective reporting might exist. 
 
VI. Analysis of Individual Newspapers 
  The first part studies each individual newspaper and its coverage of the Vioxx, Plan B, 
and Ephedra controversies. The study focuses on each newspaper separately, discussing all three 
issues within each newspaper before moving on to the next newspaper, starting with the New 
York Times, then the Los Angeles Times, and finally the Wall Street Journal.   The study focuses 
on four different research questions: (1) whether the articles are negative, positive, neutral, 
negative/neutral or negative/positive overall, (2) whether the articles are one-sided or balanced, 
(3) whether the editorials are mostly negative, positive, or neutral and (4) whether the articles 
demonstrate a liberal or conservative slant.   
 
A. The New York Times 
1. Vioxx 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
  The New York Times published 94 articles on the Vioxx controversy between October 1, 
2004 and January 1, 2006.  This time span was chosen because, as shown by the brief description 
of Vioxx, 2005 tends to be the integral point of the Vioxx controversy, when most of the news 
stories occur.  However, October and November of 2004 are also important because that is when 
the significant bad press started.  The New York Times has mostly negative articles about the 
FDA.  The results are as follows: 41 articles are predominately negative, 17 articles are 19 
negative/neutral, 18 articles are neutral, 6 articles are neutral/positive, and 12 articles are 
predominantly positive.  This means that 44% of the articles are negative, 19% of the articles are 
neutral, 13% of the articles are positive, 18% of the articles are negative/neutral, and less than 
6% of the articles are positive/neutral.  Figures 1 and 2 below depict these findings graphically.  
When one combines the negative/neutrals with the negatives and the positive/neutrals with the 
positives, the actual percentages change to 62% negative, 19% neutral, and 19% positive.  See 




  What are the coding criteria used to determine if an article should be labeled positive, 
positive/neutral, neutral, negative/neutral or negative?  An article is positive when it either 
praises the FDA for its efforts to deal with the problem or addresses the FDA’s preventive and 
proactive measures to try to get Merck to work on the problem.  For example, in an article 
entitled “For Merck, the Vioxx Paper Trail Won’t Go Away” the author refers to the FDA’s 
efforts to add warnings, noting further that Merck scientists’ are dismissing the FDA 
Figure 3: The New York Times Vioxx Positive, Negative, 















recommendations from the FDA scientists as “untrustworthy.
26”  The article implicitly is 
blaming Merck rather than the FDA.  Another example is an article entitled “Risky Drugs: A 
Patient’s Choice” in which the author, in an editorial, explains that the FDA is in an impossible 
position and has not really done anything wrong.
27  The editorial is meant to highlight the 
challenges facing the drug manufacturers and the FDA, specifically referencing the relationship 
to doctors.  An article is positive/neutral when the overall article is discussing the negative 
controversy, but does not place any blame on the FDA.  These articles lean towards the positive 
rather than the purely neutral because they imply that the FDA is moving towards a solution.  For 
example, an article entitled, “Chief Executive Quits at Merck; Insider Steps Up” makes no 
mention of the FDA’s role in the Vioxx scandal, but rather, mentions that Merck is working with 
the FDA to decide the future of Vioxx on the market.
28  Thus, this is not as positive as the 
articles that explicitly highlight or praise FDA efforts, but it is not merely neutral either because 
it implies that the FDA is working to fix the problem.  
  An article is neutral when it is not about the FDA’s role in the scandal itself, but is just 
reporting a fact about the FDA in relation to the Vioxx controversy.  For example, an article 
entitled “2
nd Trial for Merck on Vioxx Begins” mentions the FDA only to report that 
manufacturer Merck is emphasizing the FDA’s approval of Vioxx in its public and court 
statements.
29  Also, an article is neutral when it has both positive and negative aspects so that it is 
too subjective to label it one way or the other.  For example, an article entitled “Big Drug Makers 
See Sales Erode With Their Image” mentions how the FDA is possibly blocking more 
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medications than it would have or should have because of a Vioxx backlash.
30  However, the 
article is positive in that it places most of the blame on Merck rather than on the FDA.  Finally, 
an article is neutral when it blames the FDA for problems, but also talks about solutions and 
attempts at reform.  For example, one article entitled “Can Bob Dole Save Your Life? Ask Your 
Doctor” speaks about actions taken by the FDA to address advertising problems.  However, the 
article does this in a negative light, stating that “widely publicized problems prompted the FDA 
to announce that the agency would be more aggressive in monitoring ads that make unrealistic 
promises with scant mention of risks.”
31  Thus, even though the article is talking about what it 
thinks is positive change, it does so in a way that reminds the public of the negativity and bad 
press that the FDA has received recently. 
  An article is negative when it places blame on the FDA for Vioxx and only reports the 
negative aspects of the problem.  An article is also negative when it criticizes the leadership at 
the FDA or highlights numerous critical quotations from public figures outside the FDA.  One 
reoccurring storyline references acts that the FDA has done wrong.  An article entitled “Evidence 
in Vioxx Suit Shows Intervention by Merck Officials” only mentions the FDA to point out that it 
never publicly disclosed its concerns about any trial information it received from Merck.
32  
Although this is a fact, the article implies that the FDA is deceiving the public or at least not 
being forthcoming.  Also, many articles blame the FDA for not taking responsibility for Vioxx.  
In addition, frequently an article is completely unrelated to the FDA, yet randomly include some 
information about the FDA’s role in the Vioxx controversy.  For example, an article entitled 
“Drug Buyer, Beware” focuses on limiting punitive damages for consumers, yet it also remarks 
that the “FDA should take responsibility” for problems like Vioxx.  The most obvious negative 
                                                 
30 Alex Berenson, Big Drug Makers See Sales Erode With Their Image, N.Y. TIMES, Nov.14, 2005. 
31 Jane Brody, Bob Dole Save Your Life? Ask Your Doctor, N.Y. TIMES, Apr.26, 2005. 
32 Alex Berenson, Evidence in Vioxx Suit Shows Intervention by Merck Officials, N.Y. TIMES, Apr. 24, 2005. 23 
articles spend the whole time attacking the FDA, its regulations, and its infrastructure.
33  For 
example, one article entitled “Overdosed and Oversold,” an editorial, says that the agency is in 
need of reform and that the FDA fails to spot the warning signs.
34  The article then goes on to 
suggest that what is needed is an “updated regulatory system [that] can provide [the FDA] with 
the information [it] need[s] to come up with the right answers.”
35   
  Finally, an article is negative/neutral when it makes clear that the FDA is partly 
responsible for Vioxx, but offers some positive quotes or talks in an objective manner.  It is not 
neutral because the positive quotes are significantly outweighed by the negative commentary.  
For example, one article entitled “At FDA, Strong Drug Ties and Less Monitoring” starts off 
criticizing the FDA for its failure in monitoring and gives specific examples of some of the 
FDA’s weaknesses.
36  However, the article does mention that the FDA suffers from lack of 
resources and also offers a potential solution to the problems.
37  As such, while negative, it tends 
to offer some escape for the FDA as well as positive future developments.  Another example of 
this type of article is “Bush Nominee Wants States to Get Medicaid Flexibility” in which the 
article negatively says that “the FDA has failed time and again to ensure that unsafe drugs are 
kept off the market.”
38  However, at the same time, it quotes industry insiders saying that new 
leadership in the FDA will try to restore its reputation after Vioxx.
39 
  It is hypothesized that the New York Times would have predominately negative coverage, 
albeit with some neutral coverage and very little positive coverage.  The results are close to this 
hypothesis except that there is a little more positive coverage than predicted.  Perhaps the 
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newspaper is less critical of the FDA.  However, to really understand these results, one needs to 
compare the results here to both the later topics within the New York Times and with the other 
newspapers’ similar coverage.  
Research Question 2: More One-Sided or Balanced 
Another important framing consideration is the actual content of the articles rather than 
just its overall tone towards the FDA.  The second research question addresses the coverage 
within the newspaper article:  does the newspaper give the FDA a chance to defend itself or is 
the article one-sided?  The study focuses on only predominately negative articles for this data.  
After all, the positive or neutral articles are labeled positive or neutral because they likely have 
some defense or positive reporting on Vioxx.  In addition, since the Vioxx scandal is an overall 
negative story, most articles have mostly negative commentary.  Thus, the most interesting 
question asks how negative stories about the FDA within predominately negative articles choose 
to balance the story.  Are the articles fair to the FDA?   
Note that the one-sided vs. balanced article coding tends to be the most subjective since 
many articles labeled negative/neutral might be negative to another coder.  Recall that the 
reliability test indicates that this area is the weakest for coding reliability.  Yet, by using only the 
negative articles, the only discrepancy is that some other coders might have had one or two of the 
negative/neutral articles in this category.  This should hopefully not have such a huge impact on 
the results.  The New York Times has 43 articles labeled predominately negative.  Out of those 43 
articles, 23 are one-sided whereas 20 are balanced.  This means that 53% of the articles are one-
sided and 47% of the articles are balanced.  See Figure 4 below.  This is a close divide and more 
even than hypothesized.  Does this mean the newspaper is fairly reporting on the FDA, or would 
a reader prefer to have all balanced articles with a result of 0% one-sided and 100% balanced?  25 
One can defend an even split, arguing it is a positive development given that running a 
newspaper is a business and this sometimes includes more one-sided coverage.
40  While 
understandable and possibly even the inevitable reality, this does not mean that the even split is 
preferable over a 100% balanced style. 
 
A qualitative study shows some interesting recurring patterns within the one-sided 
reporting.  One customary technique of the New York Times is to include negative coverage, but 
to make it clear that the “critics” are the ones making these negative charges, not the newspaper.  
This allows the newspaper to publish negative stories, but also appear to be objective.  For 
example, in an article entitled “Leader of FDA Steps Down After a Short Turbulent Tenure” the 
newspaper quotes numerous “critics” in the industry, saying that the FDA has a “too cozy 
relationship with industry” and that the agency has made a “mockery of the process of evaluating 
scientific evidence.”
41  The FDA is given no chance to defend with its own quotes.  This type of 
implicit frame that seems objective can arguably be the most dangerous if readers do not realize 
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the article is one-sided.  Another example is when the article is neutral overall, but manages to 
include a small harsh remark.  For example, an article entitled “Good Riddance to a Bad Drug” 
talks primarily about Merck and Vioxx, but then proceeds to call the FDA a “bystander.”
42 The 
FDA is given no defense and the sentence almost passes unnoticed.
43  This is possibly another 
framing technique since it deceptively influences the reader because the reader is only really 
learning one side of the controversy. 
  A common technique for a balanced article is when the newspaper publishes an article 
that appears to be stating the facts, but that is actually implying that the FDA is to blame.  For 
example, many extremely negative articles use weak wording and tend to paint a more neutral 
picture of the FDA.  As a result, while negative, the articles appear to be more balanced since 
they do not place blame on the FDA or explicitly point out its weaknesses, but are also not 
positive either.  Another balanced article example is when the articles do not blame the FDA 
directly at all, but then talk about structural and reform measures that might prevent this in the 
future.  While the implication is that the FDA failed, making this negative, the article also talks 
about how the problem can be fixed, a slight positive.     
Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
  Besides an overall report on the positive or negative coverage, one common place to look 
for newspaper bias is the editorials or letters to the editor (collectively called “editorials” 
hereinafter and in footnotes).  The editorials are the one time that a newspaper can deliberately 
choose articles that are subjective.  Many scholars argue that the issues discussed here are the 
most indicative of an issue or value slant of a media outlet.  
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Out of the 94 articles, 13 are editorials, or 14% of the articles.  Within these 13 articles, 1 
is positive, 4 are neutral, and 8 are negative.  This means that 31% neutral, 8% positive, and 61% 
negative.  See Figure 5 below.  Interestingly, this is very similar to the newspaper’s overall 
breakdown for negative coverage depicted on Figure 3 where 62% of the articles are negative.  
However, the positive and neutral sections do not work out quite as well, with 8% compared to 
19% being positive, and 31% compared to 19% being neutral.   
 
  The one positive editorial, mentioned above, entitled “Risky Drugs: A Patient’s Choice” 
defends the FDA, pointing out the tough position the agency is in and that it has not done much 
wrong.
44  The four neutral editorials either point out both sides of the story, or more commonly, 
offer an excuse for the FDA.  For example, one article worries that the FDA will now become 
overly cautious in the future and take away a consumers right to choose if that consumer wants 
to take Vioxx.
45  The article is not necessarily critical because it is talking about a future fear, but 
it is not positive either since it is expressing doubt in the FDA.  Another example is when an 
article mentions the FDA’s role in Vioxx, but does not color the commentary at all, simply 
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pointing out that the FDA has been criticized for its drug approval process.  Finally, an editorial 
is negative either for arguing that the FDA is almost completely to blame for the Vioxx scandal 
or that the agency is biased or subject to political whims.  For example, one editorial entitled 
“Experts and the Drug Industry” criticizes the FDA for appointing biased experts to government 
advisory panels and argues that there is an undeniable link between the drug companies and the 
FDA researchers.
46  An editorial is negative when it expresses outrage at the FDA for approving 
Vioxx, like one article which highlights that the FDA is not taking appropriate steps to resolve 
the problem after it learned critical information.
47  
Research Question 4: More Liberal or Conservative Leaning 
  Finally, the last research question focuses on the liberal or conservative slants within the 
articles.  A conservative criticism should express concern that the FDA is now becoming overly 
cautious because of Vioxx.  On the other hand, a liberal criticism should express outrage or 
criticize the FDA for being too quick to approve drugs.  This liberal/conservative divide is based 
on discussions with my professor in which we agreed on these categories for Vioxx and my own 
study of the articles.  For example, some articles mention these views and quote conservative or 
liberal pundits or groups.     
Out of 94 articles, 32 mention one of the two viewpoints.  12 of the articles complain that 
the backlash with Vioxx causes the FDA to be overly cautious.  On the other hand, 18 of the 
articles complain that the FDA is too quick to approve drugs or that the regulatory regime is 
ineffective and needs immediate reform.  Two articles mention both positions.  For example, one 
article entitled “Looking for Adverse Drug Effects” mentions both viewpoints and points out the 
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difficulty the FDA is in as a result of the differing views.
48  This works out to be 56% with a 
liberal criticism, 38% with a conservative criticism and 6% with both.  See Figure 6 below.  
These results are similar to the hypothesis for the New York Times in which it was predicted that 
there would a liberal bias, but that the discrepancy between liberal and conservative coverage 
would not be so large. 
 
2. Plan B 
  The New York Times published 62 articles on the Plan B controversy between January 1, 
2004 and October 1, 2006.  These dates are chosen because they represent the most reported 
time-period, noticeably stopping around October of 2006.   Like with Vioxx, there likely should 
be mostly negative portrayals of the FDA in these articles due to the negative subject.  However, 
notice that there are differences in the type of negativity between topics.  Vioxx is a drug that the 
FDA approved which ended up injuring or killing a small percentage of people.  Plan B, on the 
other hand, is in the news predominately in relationship to the FDA and the approval process for 
                                                 
48 Editorial, Looking for Adverse Drug Effects, N.Y. TIMES, Nov. 27, 2004. 30 
over-the-counter sales.  Is the New York Times consistent in its one-sided or balanced reporting 
and does it continue to have a liberal-slant for this topic as well? 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The results are as follows: 37 articles are predominately negative, 10 articles are 
negative/neutral, 9 articles are neutral, 1 article is neutral/positive, and 4 articles are 
predominantly positive.  This means that 60% of the articles are negative, 15% of the articles are 
neutral, 7% of the articles are positive, 16% of the articles are negative/neutral, and 2% of the 
articles are positive/neutral.  Figures 7 and 8 below depict these findings.  Like Vioxx, the 




What is a positive, positive/neutral, neutral, negative and negative/neutral article?  The 
criteria are slightly different than with Vioxx since there is no clear third party to place blame on 
like Merck.  Most articles about Plan B deal in some way with the FDA’s handling of the 
situation.  The few positive articles receive this label because they both do not criticize the FDA 
and they give a reason why the FDA is not necessarily wrong.  For example, one article entitled 
“Pharmacies Balk on After Sex Pill and Widen Fight” talks about how the FDA is pressured to 
approve the drug for over-the-counter sales and that there are more considerations for the FDA 32 
than just what popular opinion says.
49  Another similar example is when an article supports the 
FDA’s decision not to approve the drug immediately since the FDA has a bigger picture in mind, 
such as focusing on important values like teenage pregnancy.   One article entitled “What Do 
Women Want? A Pill or Much More” supports the FDA slow movement on approval since 
sexually transmitted diseases and promiscuity are important considerations to the Plan B 
approval process.
50  The one positive/neutral article entitled “Senate Leaders Postpone Vote on 
FDA Chief” does not portray the FDA negatively.  Rather, it makes clear that it is the liberal 
figures and the Democratic Party that are the real critics of the agency for being slow on 
approving the drug.
51  Thus, the article implies that this is an ideological, bias attack on the FDA.  
It is neutral, however, because this ideological point requires the reader to take an inferential step 
rather than directly stating that this is an ideological debate. 
Like with Vioxx, an article is predominately neutral when it reports an objective fact 
about the approval process or about Plan B in general rather than attacking or praising the FDA’s 
handling of Plan B.  Furthermore, an article is neutral when it reports both sides, emphasizing 
equally the need to protect teenagers from easy access to the birth control and the growing desire 
to make the preventive drug easily available.  For example, an article entitled “Nominee to Lead 
FDA” mentions both points and also leaves out biased quotes from political scholars.
52   
  An article is negative when it accuses the FDA of being too political, mentions that the 
FDA is beholden to the Bush Administration, blames the FDA for not approving Plan B quickly 
enough, or scolds the agency for basing decisions on “theology” and “ideology” rather than on 
“science.”  For example, in an article entitled “Albany’s Duty on Birth Control,” the author says 
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that the FDA is bowing to the political and religious right.
53  The article states that the agency is 
using ideology to make decisions rather than the more appropriate scientific evidence.
54  This 
science over ideology line is quite common throughout many articles on this topic.  For example, 
another article entitled “Contra-Contraception” in the New York Times Magazine exclusively 
reports on how the FDA is acting based on politics rather than on science.
55  The article then 
goes on to criticize the opposing arguments, accusing the FDA of hiding behind a promiscuity 
rationale that makes little sense.  The article says that the FDA’s response to Plan B is 
representative of how the current Administration entangles political science and religious 
beliefs.
56  An article is also negative when it directly criticizes the FDA for its handling of the 
controversy.  For example, one article entitled “FDA Approves Broader Access to Next-Day 
Pill” mentions how the FDA’s image overshadows its impact on public health.  The article points 
out that there are many opinions out there, but that the FDA must realize that it is the agency in 
the spotlight and it has yet to master how to handle the differing views.  
   Finally, an article is negative/neutral when it just reports what the FDA is doing, but 
unlike the neutral articles, it manages to include noticeable critical quotes.  For example, an 
article entitled “FDA Gains Accord on Wider Sales of Next Day Pill” talks objectively about the 
original delay and the FDA’s promise to make a decision.
57  Yet, it does not stop there.  The 
articles then points out that many critics think that political considerations are involved with the 
FDA’s actions.
58  A similar example is when an article is more balanced in that it articulates the 
opposing considerations, yet this neutral reporting is overshadowed by the amount of negativity 
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in the article.  For example, one article entitled “FDA Shifts View on Next Day Pill” includes 
quotes from FDA officials explaining that Plan B approval is simply part of a decision making 
process.
59  However, the article is also engulfed with critical quotes.  Hillary Clinton is quoted as 
saying that the FDA is practicing “delay tactic[s]” and that it is clearly entangled with the 
stubborn health policy debates of the Bush Administration.
60  
  It was hypothesized that there would be predominately negative coverage, albeit balanced 
with a respectable amount of neutral articles.  This is true except that there are more negative 
articles than predicted.  As compared to Vioxx with 62% negativity, the New York Times is much 
more negative in its Plan B coverage with 77% negativity.  
Research Question 2: More One-Sided or Balanced 
The second research question addresses balance and points out any interesting framing 
techniques within the articles.  Like with Vioxx, this section uses only the negative articles.  The 
New York Times has 37 articles that are predominately negative.  Out of those 37 articles, 26 are 
one-sided whereas 11 are balanced.  Recall again that this is very subjective.  For example, much 
of the positive support for the FDA (such as emphasizing the need to consider teen pregnancy) 
might actually be perceived as a negative criticism of the FDA for being too conservative.  The 
percentage breakdown is 70% one-sided and 30% balanced.  See Figure 10 below for the 
graphical depiction.  For Vioxx, the split is 53/47.  Thus, the New York Times is apparently not 
only more apt to publish negative articles on Plan B over Vioxx, but it is also more skewed in the 
article contents.  Why might this be the case?  One possibility is that Plan B offers a more clearly 
recognized liberal and conservative position (which will be addressed in more detail below).  In 
other words, the conservative values of family, abstinence, and religious respect are more 
                                                 
59 Stephanie Saul, FDA Shifts View on Next Day Pill, N.Y. TIMES, Aug. 1, 2006. 
60 Id. 35 
recognized in the general public as a conservative value than a fear that the FDA is being overly 
cautious.  The New York Times is constantly being categorized as a “liberal” newspaper.  If this 
categorization is correct, then it makes sense that for issues that lend themselves easily to liberal 
values, one might find a more one-sided reporting on that topic (if the liberal values mean 
negative press and the conservative values mean positive press, as is the case here).  
 
A qualitative study shows some interesting recurring patterns within the reporting.  
Similar to the Vioxx example, one pattern within the one-sided coverage is to include quotes 
from important political figures.  For example, Senator Clinton is constantly referenced in the 
articles, calling the Plan B decision “long overdue” and criticizing the agency for its ties to 
Bush.
61  Other articles report on a new development (like when a person quits the FDA), but, at 
the same time, includes quotes from an involved individual that is clearly biased.  For example, 
an article entitled “FDA Consultant Quits over Contraceptive” mentions a quitter’s quote where 
he says that he quit “in protest over the handling of Plan B.”
62  The article then goes on to 
mention more critiques of the FDA using the speakers quotes, including the politics vs. science 
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distinction.
63  There is no chance for the FDA to defend itself.  While the New York Times tries 
to appear objective by including quotes rather than personal commentary, it also chooses which 
quotes to include.  Not choosing positive quotes or responses from FDA officials is itself a type 
of framing.  
Another framing technique is the choice of adjectives or words used.  For example, an 
article entitled “New Chief for Women’s Health Office” mentions that a new person has been 
appointed due to a “delayed decision” on Plan B.
64  Although it appears to be objective, the 
“delayed” adjective implies that the FDA should have made a decision already and has 
inappropriately not done so.  The article colors the commentary in what might appear to be an 
objective manner. 
  Another interesting pattern is where the newspaper places the negative quotes.  In the 
New York Times coverage, the stories usually begin and end with the negative quotes.  If the 
article does not use quotations, it still tends to open with a very negative sentence or have a 
negative title.  For example, one article is entitled “Politics as Usual, and Then Some.”
65  Before 
one even reads the article, the FDA is already being accused of playing politics.  The more 
balanced articles show a similar theme where the positive quotes tend to be closer to the middle 
of the articles or at the very end after a long tirade about the FDA’s failures.  Thus, even the 
balanced articles are arguably one-sided in framing since they include the defensive quote or 
sentence in an easily overlooked place. 
Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
  The third research question asks about the issues reported on in the editorials and whether 
the editorial is negative, positive, negative/neutral, positive/neutral or neutral.  Recall that 
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editorials are interesting since the newspaper can choose articles that intentionally express a 
particular political belief.  As contrasted with Vioxx, Plan B coverage has many more editorials.  
Out of the 62 articles, 21 articles are editorials or 34% (as compared to 14% for Vioxx).  Within 
these 21 articles, 2 are positive, 1 is neutral, and 18 are negative.  This works out to be 5% 
neutral, 10% positive, and 85% negative.  See Figure 11 below.  Unlike Vioxx, the numbers here 
do not correspond as well to the overall reporting of the newspaper on this topic where only 77% 
of the articles are negative.  The number is even lower when one includes the middle categories 
at only 60% negative.   
 
  These results are particularly interesting because it might indicate a liberal bias.  An 
article has a conservative bias when it tends to address issues of teen pregnancy/unprotected sex.  
On the other hand, an article has a liberal bias when it tends to address science, ideology or ties 
to the Administration.  For example, if the article is defending the FDA for protecting teenagers, 
the author is expressing a conservative view.  Yet, these numbers at least lead to the conclusion 
that the New York Times shows a propensity to criticize the FDA rather than praise it.  Whether 38 
this is a liberal bias against the current Administration or just a reflection of the negative story 
depends on the editorial contents.  
When one looks at the contents, however, it does appear that many of the negative 
articles address the liberal viewpoint and the positive articles address the conservative viewpoint.  
The two positive editorials praise the FDA for its handling of the drug.  For example, as 
mentioned above, the article entitled “What do Women Want? A Pill, or Much More?” supports 
the FDA for its concern for promiscuity.
66  On the other hand, many articles reference the 
influence of the Bush Administration and politics on the FDA.  For example, one editorial 
entitled “Science or Politics at the FDA?” talks about how the delay at the FDA to approve this 
drug is “scary” since it might represent religious and political pressure.
67  The few negative 
editorials that do not address this topic just blame the FDA for the delay and complain that there 
is no real excuse for it.  The one neutral editorial is a short letter complaining that the New York 
Times does not report fairly on the Plan B issue, stressing that the topic is “sensitive” and that the 
newspaper should give more information about the safety of the drug.
68  The article does not 
really criticize the FDA. 
When compared to Vioxx, this reporting again seems to be more negative overall.  One 
possible reason is that the public who writes the letters to the editor hears the same criticism over 
and over again.  The “ideology over science” line is so common in the articles that it is not 
surprising that ordinary citizens might cling to this critique as compared to Vioxx which has 
more positive themes for the FDA, such as third parties.  
Research Question 4: More Liberal or Conservative Leaning 
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  The editorials are not the only places where this liberal tendency is uncovered.  
Combining the editorials with all of the articles, out of 62 articles, 36 mention a liberal critique 
such as the Bush Administration, political ideology, or some type of political or religious 
influence on the FDA.  Only 10 mention conservative values such as protection of children.  Out 
of those 10 articles, 5 also mention the liberal side.  Thus, only 5 articles focus predominately on 
the conservative values.  This means that roughly 78% of the overall articles are supportive of a 
liberal agenda, 11% of the articles take a more balanced stance and included both sides of the 
story and 11% of the articles (40% of which are the positive editorials mentioned above) 
articulate a conservative view.  See Figure 12 below.   
Note that unlike with Vioxx, where both the liberal and conservative sides are negative 
for the FDA, here the conservative side is supportive of the FDA.  As a result, it seems that most 
of the conservative articles also tend to be the positive or neutral articles.  As with the other 
results, there is a much higher propensity for liberal reporting than with Vioxx where only 56% 
of the articles are liberal and 38% are conservative.  Again, one explanation for this difference is 
the more clearly defined liberal and conservative values on this topic.   
 40 
3. Ephedra 
The New York Times published 35 articles on the Ephedra controversy between January 
1, 2002 and January 1, 2004.  Notice that this number is much smaller than the New York Times 
Vioxx and Plan B coverage.  One possible reason is that the topic is less “interesting” than the 
other two: since not everything about Ephedra is negative, it might be considered less 
newsworthy.  Although Ephedra is a negative story overall, many commentators do not think that 
the FDA necessarily handled the Ephedra problem incorrectly, especially during this time period 
as compared to earlier failed efforts.  Given this difference, it should be interesting to see if the 
more liberal papers still criticize the FDA more than the more conservative papers.  It was 
hypothesized that since the New York Times has liberal reputation, it might include critical 
articles on the FDA and the Bush Administration indirectly rather than bother to report on 
positive stories or viewpoints.  Surprisingly, this hypothesis was incorrect. 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The results are as follows: 6 articles are predominately negative, 2 articles are 
negative/neutral, 15 articles are completely neutral, 4 articles are neutral/positive, and 8 articles 
are predominantly positive.  This means that 17% of the articles are negative, 43% of the articles 
are neutral, 23% of the articles are positive, 6% of the articles are negative/neutral, and 11% of 
the articles are positive/neutral.  Figures 13 and 14 below depict these findings graphically.  Like 
the other examples, combining the negative/neutrals with negatives and the positive/neutrals with 
positives, changes the percentages to 23% negative, 43% neutral, and 34% positive.  See Figure 




What does a positive, positive/neutral, neutral, negative/neutral, or negative article mean 
in the Ephedra situation?  An article is predominately positive when it praises the FDA for its 
decisions or when it blames a third party for any Ephedra problems.  For example, an article 
entitled “Complaints and Support for Diet Pill at Congressional Hearing” highlights how the 
FDA cannot be blamed for any developments that occur when a third party lies about 
symptoms.
69  Many articles, such as one entitled “Baseball: Officials Urges Ban of Ephedra by 
Baseball” takes the opportunity to point out that the FDA is just trying to do its job with 
Ephedra.
70  There is no negative criticism or accusations against it.  Other articles go even further 
by placing blame directly on others.  For example, one article entitled “Books on Health: 
Sometimes, the Labels Lie” expressly places blame on the Dietary Supplement Act as the cause 
of the FDA’s failure to stop these type of products from getting on the market.
71  The article 
points out that even if the FDA does everything right, the Act will still work against it.
72   Other 
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articles simply express how the FDA is on top of the problem and aware that it must be dealt 
with quickly. 
The positive/neutral articles do not fit into the predominately positive criteria because 
they praise the FDA in a less direct, positive way.  For example, an editorial entitled “Danger of 
an Herbal Supplement League” does not criticize the FDA, but rather articulates how the author 
hates the law at issue in this case.
73  The author makes clear that he thinks the FDA needs more 
evidence and implies that, in the future, the FDA might be more to blame.  However, future fear 
is not a strong critique and the article is still positive overall.  Another example is where the 
article points out the tough situation the FDA is in like “Expert Panel Finds Flaws in Diet Pill 
Safety Study.”
74  The article is not predominately positive because it is not providing a third 
party to blame or praising the FDA.  Rather, it is blaming the FDA’s structure itself and implying 
that the FDA is working within its limited resources.
75  
Many articles on the Ephedra coverage fall in the neutral category.  These articles take a 
very objective approach, simply reporting on the FDA’s structural and legal constraints and on 
what it is doing to work towards getting Ephedra off the market.   Like with the previous 
examples, an article is neutral when it has little to do with the FDA’s handling of the situation.  It 
might point out the need for reform in an objective, uncritical way.  For example, one article 
entitled “US to Prohibit Supplement Tied to Health Risk” highlights how citizens might have 
been unhappy with the amount of time Ephedra remained on the market, but that most 
understand the difficult regulatory position the FDA is in for situations such as this.
76  This 
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article is not positive because it is not praising the FDA at all, but it is also not negative because 
it is expressing understanding. 
  An article is negative when it tends to accuse the FDA of not doing enough on Ephedra 
or says that the government is simply ignoring the situation.  For example, one article entitled 
“Pro Football Back in High School, Vick was Far From Being the Running Man” mentions that 
the government is simply not acting fast enough.
77  The author wants the FDA to regulate the 
dietary supplement industry and blames it for the largely unregulated arena that existed in 
2002.
78  Another common negative theme is when an article speaks only of the FDA as being 
“weak” due to its regulatory and legal restrictions.  This is negative and not neutral because the 
word choice paints the FDA as a powerless agency that is stuck doing what others tell it to do.  
This is different from the positive articles that use the weak laws as a reason to take blame away 
from the FDA or the neutral articles that used the weak laws as a fact.  For example, an article 
entitled “After a Pitcher’s Death, Marketers of Dietary Supplements Try to Dodge the Taint of 
Ephedra” only mentions the FDA to make certain that people know the FDA is weak and “lacks 
power to ban them” itself.
79  Other articles criticize the FDA for its lack of real data on the issue.   
Finally, an article is negative/neutral when it expresses praise that the FDA finally 
entered the debate and acted on the issue, but does so in a way that makes it clear that the FDA 
should have acted more effectively earlier and handled the situation better.  One article entitled 
“FDA to Put New Rules on Dietary Supplements” praises the FDA for acting, but points out that 
it could have imposed good manufacturing standards and that this is “long overdue and 
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inadequate.”
80  The article goes on to lament the absence of strong FDA enforcement.  
Accordingly, it is neutral because of the overall praise, but the criticisms make it more negative.   
This is quite different than the results from Vioxx and Plan B.  Here, the predominantly 
negative articles have a lower percentage than the neutral and the positive articles.  Since 
Ephedra is arguably a more positive story overall than the other examples, the fact that the New 
York Times reported positively on the FDA might mean it reports objectively, based on the story 
topic rather than on bias or agenda.  On the other hand, the real test will be to compare its 
Ephedra coverage with other newspapers to see if it falls in line with these newspapers coverage 
or whether it tends to still have less positive or neutral articles for a more positive story. 
Research Question 2: More One-Sided or Balanced 
The second research question addresses the balance within the articles.  Do the negative 
articles tend to give both sides or rather focus only on the negative criticisms?  The New York 
Times has 6 articles that are predominately negative.  Out of those 6 articles, 4 are one-sided and 
2 are balanced.  This means that 67% are one-sided and 33% are balanced.  See Figure 16 below.  
This falls in the middle of the Vioxx and Plan B reporting where there is a 53/47 Vioxx split and 
a 70/30 Plan B split.  Surprisingly, these results have a wider split than Vioxx.  Since the story is 
more positive, one might think that the negative articles would try to include more positive 
coverage.  Perhaps this is indicative of a negativity towards the FDA.  On the other hand, it 
might be that when the New York Times decides to publish the negative articles, it chooses to 
focus on the negativity to counterbalance against the more positive and neutral articles overall.  
Another explanation might be the small number of articles as a basis for percentage breakdowns.  
Due to this problem, it is difficult to see any real patterns.  On a side note, there does not seem to 
be any particular consistency in the placement of negative or positive quotations.  
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Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
  The third research question addresses the content within editorials, specifically focusing 
on any liberal or conservative bias.  Unfortunately, the editorial study does not work for this 
topic since only one article is an editorial.  The article is entitled “Danger of an Herbal 
Supplement League” which criticizes the law, but tends to be neutral on the FDA’s role, not 
criticizing the FDA for not banning the drug right away without more evidence.  The author 
implies that he supports the FDA’s decisions thus far.
81   
Research Question 4: More Liberal or Conservative Leaning 
  As with Vioxx and Plan B, editorials are not the only places to uncover value-laden 
reporting.  Out of all 35 articles, 5 tend to have a liberal bias, 6 tend to have a conservative bias, 
and 1 mentions both points of view.  Here a liberal and conservative bias is very hard to define.  
Something is liberal when it criticizes the FDA as compared to a conservative article that offers 
more positive support for the cautious, studied approach.  The small number reflects the facts 
that most of the articles do not really criticize the FDA in either direction.  Rather, they mostly 
report on the facts, such as the warning label requirements.  In addition, many articles discussed 
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above place blame on the regulatory system or talk about the legal restrictions placed on the 
FDA.  It is unclear whether these types of articles fit a liberal or conservative agenda and it is 
possible it really supports neither.  Thus, based on the small number of articles, there is a 50% 
conservative focus, 42% liberal focus, and 8% use both viewpoints.  See Figure 17 below.   
These results are much more balanced when compared to the 78/11 split for Plan B and 
the 56/38 split for Vioxx.  One reason might be the small sample and the lack of adequate frames 
for a liberal or conservative viewpoint.  Another explanation is that this topic lends itself to more 
praise of the FDA than negative liberal criticism and so the newspaper should include more 
positive conservative viewpoints in the articles.  
 
 48 
B. The Los Angeles Times 
1. Vioxx 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The second newspaper is the Los Angeles Times.  That newspaper published 68 articles 
on the Vioxx controversy between October 1, 2004 and January 1, 2006.  Like the New York 
Times, the Los Angeles Times also has more negative articles overall than positive or neutral 
articles.  The results are as follows: 41 articles are predominately negative, 5 articles are 
negative/neutral, 14 articles are neutral, 0 articles are neutral/positive, and 8 articles are 
predominantly positive.  This means that 60% of the articles are negative, 21% of the articles are 
neutral, 12% of the articles are positive, 7% of the articles are negative/neutral, and none of the 
articles are positive/neutral.  Figures 18 and 19 below depict these findings graphically.  When 
combining the negative/neutrals with negatives and the positive/neutrals with positives, the 
percentages are 67% negative, 12% neutral, and 21% positive.  See Figure 20 below for the 




  As discussed in the methodology, the study uses the same coding techniques across the 
newspapers for consistency purposes.  Thus, an article is positive when it addresses the 
controversy, but does not place the FDA in a blameworthy role.  Also, articles that praise the 
FDA for any developments on Vioxx are classified as positive.  Finally, articles that speak 
positively about the FDA’s proactive measures to work with Merck fall into this category.  For 
example, one article entitled “Product Liability Hovers Over Pharmaceuticals” blames Merck for 50 
the Vioxx controversy, faulting the company for failing to fully disclose its results to the FDA.
82  
Another article entitled “FDA Warns Aleve May Increase Heart Risks; Preliminary Findings 
Prompt Concerns on the Over the Counter Drugs and its Other Forms” talks about the positive 
developments at the FDA due to Vioxx and, specifically, how the FDA is now reacting well to 
the Aleve situation.
83  Another article entitled “FDA, Drug Companies Deny Oversight Flaws” 
publishes defensive quotes of the FDA after a former employee, David Graham, accused the 
FDA of being “incapable” of making sure that unsafe drugs did not reach the public.
84  The 
article says that the FDA “categorically reject[s] assertions that it failed to protect the public” 
and that Graham’s views do not align with the agency’s views of its safety record.
85  Although 
this article is in defensive mode, it does provide a positive forum for the FDA to explain the 
Vioxx situation, something not seen very often. 
  Like the New York Times, an article is neutral when it reports facts in an objective matter, 
talks about solutions and reforms for the FDA, or offers equally positive and negative 
assessments of the FDA’s handling of the Vioxx situation.  For example, one article entitled 
“Arthritis Drug Vioxx Pulled: Risk of Heart Attacks is Cited” simply tells about the 2004 
developments with Vioxx and mentions the FDA’s future role.
86  There is no implication yet that 
the FDA is at fault.  One point of caution is that articles towards the beginning of the Vioxx 
problem tend to be more positive since less information was known by the public.  
Unfortunately, content based on timing is beyond the scope of this study.  Another example is an 
article entitled “In the Dark About Drugs” in which the author highlights the Vioxx problem, but 
                                                 
82 Editorial, Product Liability Hovers Over Pharmaceuticals, L.A. TIMES, Sept. 3, 2005. 
83 Ricardo Alonso-Zaldivar, FDA Warns Aleve May Increase Hear Risks; Preliminary Findings Prompt Concerns 
on the Over the Counter Drugs and its Other Forms, L.A. TIMES, Dec. 21, 2004. 
84 Ricardo Alonso-Zaldivar, FDA, Drug Companies Deny Oversight Flaws, L.A. TIMES, Nov. 20, 2004. 
85 Id. 
86 Thomas H. Maugh and Denise Gellene, Arthritis Drug Vioxx Pulled: Risk of Heart Attacks is Cited, L.A. TIMES, 
Oct. 1, 2004. 51 
blames it more on a lack of government funding than on the FDA.
87  The article might even be 
positive since it is advocating for the FDA to have more powers, but since there is some direct 
criticism of the agency’s handling of Vioxx, neutral seems more appropriate.   
  An article is negative when the article blames the FDA for Vioxx, criticizes the FDA’s 
leadership and decision-making skills, or highlights numerous critical quotations from figures in 
the media.  One article entitled “An Ailing, Failing FDA” implies that the scientists at the FDA 
do not study the drugs thoroughly and accuses the FDA of silencing FDA officials who want to 
warn others about the Vioxx problem.
88  Other articles excuse the FDA of being too cozy with 
the drug companies.  For example, one article entitled “The Drug-Approval Pendulum” talks 
about how the government’s defense and explanations in the Vioxx situation sound more like a 
“buddy relationship with Merck.”
89  Other articles highlight the FDA’s failure to act quickly 
enough or, on the other hand, accuse the FDA of acting too quickly to get drugs to the market.  
For example, one article entitled “FDA to Institute Safety Board: The Goal is to More Quickly 
Identify Problems with Drugs and to Issue Alerts” talks about how the FDA is under pressure for 
its failure to act quickly on evidence it received about potential drug problems.
90  The article 
expresses a longing for a change of a culture and points out that consumer confidence is shaken 
due to the FDA’s handling of Vioxx.
91  On the other hand, other articles such as “Acting Chief is 
Nominated to Lead FDA” mention how in the past the FDA has been accused of being too 
cautious, (like with AIDS) but now it is turned in the opposite direction and is too quick to 
approve drugs.
92  
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  Finally, an article is negative/neutral when it places blame on the FDA, but also offers a 
significant amount of positive quotes or defenses for the FDA.  For example, an article entitled 
“It’s a Maybe for Drug Safety Unit” talks about FDA’s lax enforcement and monitoring in this 
situation, but then goes on to imply that change is underway and that the FDA is trying to 
improve.
93  The article is still negative, but the improvement sentences provide some neutrality 
missing from many of the negative articles.   
  It was hypothesized that there would be predominately negative articles on the Vioxx 
controversy, or, conversely, that there would be very few positive articles.  This seems to be the 
case.  However, the more interesting results are in the balance split and the liberal/conservative 
bias because the topic lends itself to negative FDA coverage. 
Research Question 2: More One-Sided or Balanced 
The second research question studies the content of the articles, noting whether a 
negative article is one-sided or balanced.  The Los Angeles Times has 41 articles that are 
predominately negative.  Out of those 41 articles, 15 are one-sided whereas 26 are balanced.  
This means that 37% are one-sided and 63% are balanced.  See Figure 21 below.  This is in line 
with the hypothesis that a significantly higher number of articles would be one-sided rather than 
balanced. 
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An article is one-sided when it accuses the FDA of failing with Vioxx.  For example, an 
article entitled “FDA Chief Crawford Resigns” talks about the Vioxx problem and includes only 
negative quotes, saying that the agency has squandered the public’s trust and that its “reputation 
as the gold standard in public health” is now tarnished.
94  On the other hand, an article is 
balanced when it includes a positive or neutral quote or idea, but not enough to make the article 
negative/neutral.  For example, many negative articles talk briefly about the future.  One article 
entitled “FDA Warns of Celebrex Heart Risk” mentions how the “public is left wondering when 
the next shoe will drop” but then includes a FDA defensive quotation saying that the system is 
improving, as Celebrex has shown.
95    
One framing pattern is the use of adjectives and nouns to describe the FDA.  For 
example, many articles choose quotes that refer to the FDA as a “failure” or “impotent.”  One 
article talks about the “beleaguered agency.”  Yet, the author of a wide majority of the Los 
Angeles Times Vioxx articles is the same person, Ricardo Alonso-Zaldivar.  As a result, it is 
unclear whether this is a framing technique of the Los Angeles Times or whether it is a stylistic 
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choice of one author.  Like the New York Times, this newspaper also tends to include a lot of 
quotations.  In fact, many articles repeat the same quotations from the same officials when it fits 
the story.  Unlike the New York Times¸ the quotations are not placed as blatantly at the beginning 
and end.  Whether this is a deliberate attempt to fairly spread out the positive and negative quotes 
or rather just a reflection of the organization of the story is unclear.  
Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
  The third research question focuses on editorials to uncover any type of issue or 
liberal/conservative bias.  Out of the 68 articles, 15 are editorials or 22%.  Within these 15 
articles, 2 are positive, 3 are neutral, and 10 are negative.  This is equivalent to 20% neutral, 13% 
positive, and 67% negative.  See Figure 22 below.  Interestingly, this is almost exactly equivalent 
to the overall breakdown of positive, neutral and negative coverage only, depicted on Figure 20.  
Overall 67% of the articles are negative, the exact same amount here.  The positive and neutral 
sections are only off by one percentage point each (12% for positive and 21% for neutral), which 
is statistically equivalent given the small number of articles.  The numbers are quite similar when 
one includes the middle categories in Figure 19, with the only difference being 60% negative 
rather than 67% negative.  As such, the Los Angeles Times is at least consistent overall in the 
type of coverage it gives to Vioxx, not showing any more bias in the editorial section than in the 
whole newspaper.  However, this does not mean that the whole newspaper is not bias overall, 
which should be clearer in the newspaper comparison.  55 
 
  The positive editorials blame Merck and accuse the company of deliberately trying to 
hide things from the FDA.  The neutral editorials criticize the problems surrounding the FDA 
rather than the FDA itself.  For example, one article entitled “Letting the Dogs Out” talks about 
how the FDA is “ridiculously underfunded” and how it is this funding that is responsible for 
many of the agencies problems.
96  A negative editorial is usually highly critical of the FDA, 
either calling it names such as the “failing FDA” or accusing the agency of suffering from 
communication and political problems.  For example, one article accuses the FDA of failing to 
enforce its own rules.  Other articles, such as “Murky Merck” directly state that the FDA “clearly 
failed in their regulatory duties.”
97  The article then blames Congress for not giving the FDA the 
powers it needs.
98  
Research Question 4: More Liberal or Conservative Leaning 
  The final question directly addresses the liberal or conservative tendencies of the 
newspaper throughout all the articles.  An article is liberal when it mentions that the agency is 
too quick to approve drugs.  On the other hand, an article is conservative when it complains 
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about the FDA becoming too cautious.  Out of the 68 articles, 4 articles support a conservative 
view, expressing fear that Vioxx has resulted in an overly cautious FDA.  However, most of 
these articles only mention this briefly.  For example, one article entitled “Drug to Test FDA’s 
Risk Tolerance After Vioxx” talks about how the FDA might become too cautious due to Vioxx 
and says that the industry will be watching the FDA to figure out what type of stance it is going 
to take on drug approval.
99  On the other hand, 9 articles support a liberal view, expressing 
adamant disapproval of the FDA’s lax approval regime, blaming the drug company for being too 
quick to approve drugs or, alternatively, implying that the agency is in need of a regulatory 
reform or legal overhaul.  Yet, unlike the New York Times, notice that only 14 articles fit either 
criteria.  Interestingly, most negative articles deal very little with the FDA being too quick to put 
drugs out or being too cautious.  Most of the critical articles deal with the public’s bad 
impression of the FDA or its lack of resources.  Many articles talk about the lack of transparency 
and the FDA’s possible influence over scientists.   
This means that roughly 64% of the articles mentioned a liberal value, 29% of the articles 
mentioned a conservative value, and 7% mentioned both.  See Figure 23 below.  This is very 
similar to the hypothesis that the Los Angeles Times should have a clear liberal bias, the most of 
any of the newspapers.  Yet, a quarter of the articles do include a conservative value, so it is 
possible that the Los Angeles Times is more objective than its reputation suggests. 
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2. Plan B 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
  The Los Angeles Times published 41 articles on the Plan B controversy between January 
1, 2004 and October 1, 2006.  Like with the New York Times, this section compares the reporting 
techniques within the Los Angeles Times between the three topics.  The results are as follows: 23 
articles are predominately negative, 8 articles are negative/neutral, 5 articles are neutral, 1 article 
is positive/neutral, and 4 articles are predominantly positive.  This means that 56% of the articles 
are negative, 12% of the articles are neutral, 10% of the articles are positive, 20% of the articles 
are negative/neutral, and 2% of the articles are positive/neutral.  Figures 24 and 25 below depict 
these findings graphically.  Like Vioxx, combining the negative/neutrals with negatives and the 
positive/neutrals with positives, change the percentages to 71% negative, 18% neutral, and 11% 
positive.  See Figure 26 below for the graphical depiction.    
It was hypothesized that there would be predominately negative coverage.  When one 
looks at the coverage without the negative/neutral and positive/neutral categories, the amount of 
negative coverage is quite high.  As compared to Vioxx with 67% negativity, the Los Angeles 58 
Times (like the New York Times) appears to be slightly more negative on Plan B with 71% 
negativity.  Although the numbers are also close when one includes the middle neutral categories 
(60% for and 56% negative for Plan B), the major discrepancy between the two topics is the 
neutral and neutral/negative percentages.  Vioxx reporting has more neutral articles rather than 
negative/neutral (21% and 7%) as compared to Plan B reporting (12% and 20%).  However, 
since the negative/neutral is the most unreliable category, as demonstrated by the reliability test, 
this might not be as significant.  This at least shows an overall tendency of the Los Angeles 
Times to report similarly between topics on a negative drug story affecting the FDA. Whether 





Like with Vioxx, this section uses the same criteria as the New York Times for deciding 
whether something is positive, positive/neutral, neutral, negative, or negative/neutral.   An article 
is labeled positive because it does not criticize the FDA at all and places blame somewhere else.  
An article might also support the FDA’s actions in not rushing to approve Plan B.  One article 
entitled “Logic is Misguided on Foolproof Drug Plan” mentions that people must understand 60 
how easy access to plan B is not necessarily in the best interest of everyone.
100  Another article 
entitled “Morning After Pill as a Morality Problem” acknowledges that perhaps ideology played 
a role, but argues that the ideological view here might be the right morals to live by.
101  One 
important framing consideration is that all the positive articles are editorials.  The one 
positive/neutral article entitled “Survey Finds Many are Misinformed on Access to Morning-
After Pill” talks about how the FDA advisors recommended the approval.
102  The article is not 
directly criticizing the FDA, but only mentions that the public is confused about what is 
accessible on the market right now.  This could have easily been a neutral article only, but it 
tends to have a more positive tone.  
An article is neutral when it simply states the facts and talks about the FDA’s role in a 
purely objective manner.  For example, an article entitled “Questions & Answers: the Morning 
After Pill” published in 2006 states that the FDA has approved the drug and might soon approve 
it for over-the-counter.
103  There is no mention of any previous FDA delay tactics.  Another 
typically neutral article entitled “Birth Control Patch Might Raise Clotting Risk More Than a 
Pill” references the resignation of a worker due to delays with Plan B.
104  However, the article 
only quotes the worker for an unrelated issue and simple reports the Plan B information to 
inform the reader why the worker is no longer with the agency.
105  Other examples are in the 
articles towards the end of the controversy once the drug had been approved.  One article entitled 
“FDA Age Restriction on Plan B is too Limiting” calls the approval “bittersweet” and expresses 
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happiness that the decision has been made.
106  However, the article implies that approval took 
too long and argues that much still needs to be done, specifically when dealing with age 
restrictions.
107   
  An article is negative when it accuses the FDA of placing ideology above science and for 
being beholden to the Bush Administration.  For example, one article entitled “FDA Suggests 
Warnings on Condoms” includes a quick remark at the bottom of an unrelated article that the 
FDA is in a controversy between science and sexuality and that it has chosen to postpone an 
obvious decision “despite evidence showing the drug is safe.”
108  Another illustrative example is 
entitled “Bush and the Mad Scientists” in which the article reprints oft-repeated quotes that the 
FDA makes a mockery of the process of evaluating scientific evidence and that this is a low 
point for the FDA.
109  Furthermore, an article is negative if it simply accuses the FDA of making 
a bad decision without any mention of political influence.  For example, an article entitled “A 
Bitter Pill” talks about how the evidence shows it should be approved, yet the FDA still has 
chosen to drag its feet.
110   
  Finally, an article is negative/neutral when it includes significant and noticeable critiques 
about the FDA in an article that is otherwise neutral.  For example, an article entitled “Cervical 
Cancer Vaccine One Step From Approval” is not even about the Plan B drug, yet the article 
manages to throw in one sentence about how the FDA has not acted yet on this drug.
111  Due to 
the small mention and the fact that this remark is technically true, the negative/neutral is more 
appropriate as compared to the negative only.   
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Research Question 2: More One-Sided or Balanced 
The second research question asks whether the Los Angeles Times is more one-sided or 
balanced in its negative coverage.  The Los Angeles Times has 23 articles that are negative.  Out 
of those 23 articles, 16 of are one-sided and 7 are balanced.  This means that 70% of the articles 
are one-sided and 30% of the articles are balanced.  See Figure 27 below.  When compared to 
Vioxx at 63/37, the Los Angeles Times is slightly more likely to be one-sided for Plan B.  This is 
similar to the results in the previous paragraph where we see that the newspaper is slightly more 
negative overall for Plan B.  As the New York Times analysis mentioned, one plausible reason 
here might also be the more clearly defined liberal and conservative positions.  Like the New 
York Times, the Los Angeles Times has a reputation for being a liberal newspaper.  As such, 
when there is an easier-to-define liberal viewpoint, it is not surprising that slightly more articles 
report only a liberal, negative, one-sided view rather than a conservative, positive view. 
 
An article is one-sided when it only reports on negative public opinion about the FDA’s 
handling of the Plan B drug.  Many of these articles articulated liberal values, addressing issues 
such as ideology and political influence.  For example, an article entitled “Plan B Cleared for 63 
Sale Over the Counter” mentions all the political controversy surrounding the decision and 
publishes quotes that the FDA has “caved into pressure from reproductive rights” and that the 
previous decisions have “nothing to do with science.”
112  The more balanced articles talk about 
how the morale at the FDA is down and that Plan B is now a political issue that is interfering 
with the FDA.  On the other hand, it also offers an excuse for the FDA like its place in the 
government and lack of funding.  For example, a negative article entitled “FDA’s Actions on Pill 
Faulted” gives the FDA a chance to defend itself very briefly, but then quickly dismisses the 
arguments.
113  One interesting framing technique here is the repeated use of the same line in the 
articles.  The Los Angeles Times constantly mentions the same science over ideology line, so 
much so that it became prudent to label the line with its own symbol during initial coding.  When 
a newspaper persistently uses the same line, even if it is not something it originally said, it 
provides a much greater opportunity for that line to stick in the public’s mind.  
Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
  The third research question attempts to study the types of issues that the newspaper 
chooses to report on in the editorials.  Specifically, editorials might bring out a liberal or 
conservative slant.  If the article mentions support for the fast approval of the pill or mentions 
that the FDA is being ruled by ideology or the Bush Administration, the article is more liberal-
leaning.   On the other hand, if the article highlights sexuality and “morality” as important 
considerations and offers praise for the FDA’s thought-out approved, it is more conservative-
leaning.  Out of the 41 articles, 12 are editorials or 29% (as compared to 22% for Vioxx).  Within 
these 12 articles, 3 are positive, 1 is neutral, and 8 are negative.  This is 8% neutral, 25% 
positive, and 67% negative.  See Figure 8 below.  Like with Vioxx, the editorial Plan B numbers 
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are close to the overall Plan B coverage, albeit with a little less positive coverage overall and 
more neutral coverage instead.  Here 67% are negative as compared to 71% negative overall (see 
Figure 26).  However, 25% are positive and 8% are neutral here, as compared to 11% and 18% 
overall.  When one includes the middle neutral categories, the coverage is not as close with 56% 
negative, 10% positive and 12% neutral (See Figure 25). 
 
  Like with the New York Times, it is possible that these results indicate a liberal bias.  
Seven of the eight negative editorials do depict some type of liberal argument.  For example, one 
article entitled “FDA Has a Deal for Plan B Pill” mentions how the FDA is “embarrassed into 
approving the pill” and that the announcement comes at an “awfully convenient time.”
114  
Another example is an article entitled “Birth Control Too?” in which the author equates the FDA 
to the Bush Administration and uses the similar sounding morality over science line to express 
her point.  Note that this might be indicative of a liberal bias or it might mean that the criticism 
of the FDA on this topic happens to represent a liberal viewpoint.
115  It is possible this is not a 
bias at all, but that the newspaper is reporting the bad press presently in the public conscious. 
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The positive editorials, on the other hand, talk about the importance of the morality issue.  
One article (mentioned previously) entitled “Morning After Pill as a Morality Problem” talks 
about how morals are important and should not just be dismissed so easily.
116  The one neutral 
article (also mentioned previously) entitled “FDA Age Restriction on Plan B is too Limiting” 
says the decision is “bittersweet,” but then criticizes the FDA for taking so long.
117  
There is an identical percentage of negative coverage here as with Vioxx.  However, the 
positive and neutral sections are again switching off (25/8 for Plan B as compared to 13/20 for 
Vioxx).  Vioxx editorial coverage is more neutral than positive, whereas here Plan B coverage is 
more positive than neutral.  One possible reason for this distinction is that the conservative 
viewpoint for Plan B tends to be a positive article whereas for Vioxx the conservative viewpoint 
is also a negative critique (just a different one).  Thus, it is not surprising that there are more 
positive articles here than in Vioxx.  
Research Question 4: More Liberal or Conservative Leaning 
   Next, the study looks at all the articles for any liberal or conservative bias as defined 
previously.  Out of the 41 articles, only 5 of the articles articulate the conservative viewpoint.  14 
of the articles mention the liberal viewpoint, most pointing out that the FDA is listening to 
political pressure and ruling based on ideology.  Many of these examples have been cited 
previously in earlier examples.  One article mentions both viewpoints.  This means that 70% of 
the overall articles are liberal-leaning, 25% of the articles are conservative-leaning, and 5% 
represent both views.  See Figure 29 below.  This is also very similar to Vioxx where 64% are 
liberal and 29% are conservative.  This discrepancy, albeit small, might be due to the reason 
above.  Since more conservative arguments are positive and the Los Angeles Times reported 
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more negative articles overall on this topic than with Vioxx, it makes sense to find that the 
overall breakdown has a smaller conservative presence if there are less positive articles.  
 
3. Ephedra 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The Los Angeles Times published 33 articles on the Ephedra controversy between 
January 1, 2002 and January 1, 2004.  As with the New York Times, the amount of articles is 
significantly less for this topic than for Vioxx and Plan B.  Also, although this is a negative 
event, recall that Ephedra is the most positive story with respect to the FDA’s role.  Unlike 
Vioxx and Plan B where the FDA is directly in the middle of it, here the FDA has a more 
complicated role.
118  The FDA initially did a poor job in its approach to the Ephedra controversy.  
However, during the time period of this study, the FDA began to approach the problem in a less 
hurried, more positive way and ultimately prevailed.  Even though this time period represents a 
more positive moment in the Ephedra history, it was still predicted that the majority of articles 
would be negative overall due to the liberal leaning reputation of the newspaper which might be 
more inclined to target the FDA when the White House is held by a Republican and might be 
more likely to highlight the past failing rather than the current victory.  Again, this was mistaken.  
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The results are as follows: 5 articles are predominately negative, 5 articles are 
negative/neutral, 16 articles are completely neutral, 1 article is positive/neutral, and 6 articles are 
predominantly positive.  This means that 15% of the articles are negative, 49% of the articles are 
neutral, 18% of the articles are positive, 15% of the articles are negative/neutral, and 3% of the 
articles are positive/neutral.  Figures 30 and 31 below depict these findings graphically.  The 
combined results are 30% negative, 49% neutral, and 21% positive.  See Figure 32 below for the 




An article is predominately positive when the FDA receives praise for its handling of 
Ephedra.  For example, an article entitled “Baseball’s Mass Appeal Facing a Test” says that the 
baseball industry is “awaiting the FDA review” implying that it trusts the FDA.
119  An article is 
also positive when it places blame on a third party.  For example, in “Natural Defense Trapped 
Metabolife” the author describes Congress’s blameworthy role in the Ephedra controversy, 
talking about the “usual absurdities” resulting from interest group influence.
120  The article 
basically leaves the FDA alone.  
The positive/neutral article entitled “A Grieving Mother Urges Ban of Ephedra” talks 
about how the FDA is ultimately responsible for approval, but points out that one must consider 
the difficult position the FDA is in due to the law.
121  The author is focusing mainly on 
criticizing the law, rather than on criticizing the FDA.  It receives the neutral classification 
because it still mentions how the FDA has the responsibility.  In addition, the article also implies 
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that the FDA might be influenced by emotions.
122  However, since the overall tone of the article 
is positive with respect to the FDA, offers the FDA a defense, and places blame on the law rather 
than on the FDA, the positive/neutral label seems appropriate.   
An article is neutral for a variety of reasons.  First, an article that is simply reporting the 
facts in an objective way fits this category.  For example, an article entitled “Bill Would Bar 
Uses of Ephedra” talks about how the FDA does not regulate the dietary supplement industry.
123  
The article is attempting to explain the FDA’s relationship to Ephedra and is not attempting to 
negatively critique the agency.  Second, an article that is extremely balanced so that it is too hard 
to make a judgment call as to whether it is negative or positive leaning falls into the neutral 
category.  For example, an article entitled “Many Fans of Herb Had Moved on to Newer 
Supplements” talks about how restrictions on Ephedra are a positive thing.
124  The article says 
that “this is the first time that supplement law has actually been used to restrict.  We are laying 
out a new framework here.”  However, the article also touches on the negative aspects of the 
story, saying that health groups think this was long overdue and that the regulations in general 
mean that another dietary supplement can get on to the market just as easily.
125  Another example 
is the article “US Laws Helps to Keep Ephedra on the Market,” which represents all sides to the 
debate.
126  It talks about the regulatory problems with the law, but then gives the critics a chance 
to accuse the FDA of not acting quickly.  However, in defense of the FDA, the article mentions 
that the FDA is just being cautious, implying that this is part of the job.  It also goes on to say 
that “it is almost impossible for the government to prove that a product is safe.”
127 
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  An article is predominately negative when the FDA is blamed for Ephedra or when it is 
accused of following ideology.  For example, one article entitled “FDA Draw Fire Over Dietary 
Aids” targets the FDA for its “regulatory stance” and then proceeds to criticize the regulations in 
general.
128  The article asks why it took nine years for the FDA to act and argues that the FDA 
should not always be playing catch up, but rather should be proactive.  Another article entitled 
“Ephedra Under Intense Scrutiny” blames the FDA for not getting involved sooner.
129  The 
article quotes that “if it takes this incident to do so, it is painful, tardy, and unfortunate.”
130  The 
article is advocating for labeling rather than abandonment all together.  Another article entitled 
“A First Step Towards Standardizing Supplements” talks about how dietary supplements are 
virtually an “unregulated” category, but that the FDA should at least place good management 
settings for the industry.
131  The article accuses the FDA of only taking action against 
supplements when it is an “outrageous health claim” rather than on the wider variety of 
claims.
132  
Finally, an article is negative/neutral when it states the facts, but manages to include 
significant negativity about the FDA.  For example, one article entitled “Despite Warnings: 
Davis Took No Actions Against Metabolife” is not really about the FDA, but the article still 
includes a complaint about the FDA.
133  In addition, an article is negative/neutral when it is 
neutral towards the FDA’s current involvement, but implies that the FDA has acted too slowly in 
the past.   Finally, an article is negative/neutral when it implies rather than explicitly states that 
the FDA is controlled by the government.  For example, an article entitled “Hatch’s Cozy Ties to 
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Supplement Makers” says that Senator Hatch keeps the FDA regulators “at bay.”
134  While the 
article is mainly a complaint about Hatch, it implies that the FDA is beholden to Congress.  
Unlike with Vioxx and Plan B and contrary to the hypothesis, here more articles are 
neutral rather than negative.  This might be due to the fact that the actual story is more positive 
and there are less clearly defined liberal or conservative critiques or praise on this topic.  Like 
with the New York Times, this might mean that the Los Angeles Times is more objective than it 
appears since it appropriately has less negative coverage for a more positive debate. 
Research Question 2: More One-Sided or Balanced 
The second research question discusses the balance in the negative articles.  Does the Los 
Angeles Times report only the negative or does the article tend to give both sides when reporting 
negatively on the FDA?  The Los Angeles Times publishes only 5 articles that fit into the 
classification of negative.  Out of those 5 articles, 4 are one-sided and 1 is balanced.  This 
represents a very wide margin, with a whopping 80% one-sided compared to only 20% balanced.  
See Figure 33 below.  This number is much bigger than both Vioxx at 63/37 and Plan B at 70/30.  
Like with the New York Times, one has to consider the fact that these statistics are based on a 
sample size of 5.  If one article is differently labeled, it has a huge effect on the breakdown.  As a 
result, it is unproductive to engage in significant analysis about the discrepancy in the topics.   
One slight counterintuitive possibility is that the newspaper is actually trying to be more 
balanced.  Since more articles are neutral, perhaps the Los Angeles Times feels it needs to have 
only a few negative articles to represent both sides.  On the other hand, an objective newspaper 
should arguably represent both sides in all articles.  After all, an article is balanced if it has 
something to say positively or in defense of the FDA.  
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Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
The third research question focuses on the issues in the editorials and specifically asks 
whether there is any type of liberal or conservative bias.  The Los Angeles Times published 4 
editorials on this topic (or 12% as compared to 22% for Vioxx and 29% for Plan B) where 2 are 
negative, 1 is negative/neutral, and 1 is neutral.  This works out to be 50% negative, 25% 
negative/neutral, and 25% neutral.  See Figure 34 below.  Although this seems like a big split, 
given the small number of articles and the fact that one is negative/neutral (which my reliability 
test finds to be the most suspect category), this might actually be interpreted as an even divide or, 
alternatively, it might mean that it is impossible to make any general observations.  If one were 
to combine the negatives with the negative/neutral, then the results are 75/25.  This is more in 
line with the hypothesis which predicts that there should be more negative coverage overall.  
However, the small number still makes this result untrustworthy.  Note also that this is not very 
close to the overall coverage where 15% are negative, 15% are negative/neutral and 49% are 
neutral.   
The negative editorials accuse the FDA of being influenced by Congress.  The first 
editorial entitled “Letters to the Times: Dietary Supplements” suspects that the FDA is faking 73 
data so that it can live up to its reputation for being the drug industry protector.
135  The second 
negative editorial entitled “The Diet-Supplement Fiasco” blames the FDA for not acting quickly 
enough on the issue.
136  The one negative/neutral editorial is previously mentioned about Senator 
Hatch.  The one neutral editorial entitled “Get Ephedra Off the Shelves” blames the regulations 
rather than the FDA, but is not positive towards the agency either.
137   
 
Also, these results are difficult to compare to Vioxx and Plan B since those examples 
have positive editorials rather than a negative/neutral editorial.  Here, there are no directly 
positive editorials.  This is interesting since the Ephedra issue is the most positive as compared to 
Vioxx.  Recall that Vioxx has 20% neutral, 13% positive, and 67% negative and Plan B has 8% 
neutral, 25% positive, and 67% negative.  If one combines the negatives with the 
negative/neutral here, the numbers are similar.  75% negative is very close to 67% negative for 
both Vioxx and Plan B.  Also, the 25% neutral is similar to Vioxx.  The only difference is the 
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same neutral and positive distinction discussed earlier in the Los Angeles Times Plan B and 
Vioxx comparison.  
Research Question 4: More Liberal or Conservative Leaning 
Finally, this section focuses on liberal or conservative bias throughout the entire coverage 
rather than just the editorials.  Out of the 32 articles, only 10 articles mention a value-laden 
argument.  5 represent a more liberal bias and 5 represent a more conservative bias.  Thus, it 
appears that there is a 50/50 split between conservative and liberal.  See Figure 35 below.  The 
liberal articles tend to argue that the FDA is beholden to Congress.  On the other hand, the 
conservative articles argue that the FDA is being appropriately cautious and acting within the 
laws.  The small numbers are similar to the New York Times.  A similar reason might apply here 
for these results.  Since there is no clearly defined liberal or conservative viewpoint (the least 
clearly defined of all the topics in fact), it is not surprising that many do not address these values.   
Due to the small number of articles and the highly arbitrary conservative and liberal 
categories, one should not place any real emphasis on these numbers.  However, below is a brief 
comparison of the results to the other topics.  The Los Angeles Times Vioxx breakdown is 64% 
liberal, 29% conservative, and 7% both.  The Plan B breakdown is 70% liberal, 25% 
conservative, and 5% both.  Based on these results, it appears that the newspaper is much less 
likely to articulate liberal or conservative positions for Ephedra.  Again, the more likely reason is 
that there is a less clearly defined split here than with Vioxx and Plan B so it is harder to even 
uncover any liberal or conservative bias in the reporting.  75 
 
C. The Wall Street Journal 
1. Vioxx 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The third newspaper is the Wall Street Journal.  That newspaper published 82 articles on 
the Vioxx controversy between October 1, 2004 and January 1, 2006.  Like the New York Times 
and the Los Angeles Times, most articles should have negative coverage of the FDA rather than 
positive or neutral coverage, given the negative controversy.  The results are as follows: 25 
articles are predominately negative, 20 articles are negative/neutral, 23 articles are neutral, 4 
articles are neutral/positive, and 10 articles are predominantly positive.  This means that 31% of 
the articles are negative, 28% of the articles are neutral, 12% of the articles are positive, 24% of 
the articles are negative/neutral, and 5% of the articles are positive/neutral.  Figures 36 and 37 
below depict these findings graphically.  The combined percentages are 55% negative, 28% 




  Again, the same coding criteria is used here as was used for both the New York Times and 
the Los Angeles Times for classifying an article as positive, positive/neutral, neutral, negative, or 
negative/neutral.  An article is positive when it places blame on a third party rather than on the 
FDA.  For example, an article entitled “Vioxx Plaintiffs Seek Mistrial After Allegations on 
Merck Study” speaks negatively about Merck’s role in Vioxx and only objectively mentions the 
FDA.
138  Also, an article is positive when it actually praises the FDA’s actions.  An example 
entitled “Vioxx Verdict” defends the FDA, arguing that the agency has acted rationally given 
that the Vioxx results only cause a very small amount of heart attacks.
139  Another example 
entitled “Tough Defense: Facing Vioxx Trials, Merck Prepares to Play Hardball” says that the 
FDA proceeded correctly when it advocated for warning letters.
140  The article implies that the 
FDA is on top of the situation.  Similarly, an article is positive/neutral when it mainly talks about 
the FDA objectively, but has a positive inference.  For example, an article entitled “Merck’s 
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Lawyer Goes on Offensive During Closing” cites the FDA’s statement that a low-dose, short 
term use of Vioxx is acceptable.
141  The article does not directly praise the FDA or blame 
someone else, but the quotation implies that the FDA is currently studying and working on the 
Vioxx situation.   
  An article is neutral when it reports objectively on the facts, offers an even divide of 
positive and negative statements, or talks about reform efforts since Vioxx.  For example, one 
article entitled “FDA Seeks More Data on Diabetes Drugs” discusses how Merck’s main defense 
is its dependence on the FDA.
142  The article, however, simply reports the defense strategy and is 
not meant to accuse the FDA.  It is only a fact about an ongoing court case.  Another example is 
an article entitled “With Risks of Painkillers Unclear, a Long-Term Study is Proposed” that talks 
about what the FDA is doing and what the panel recommended, but places no blame on the FDA 
at all.
143 
  An article is negative when it accuses the FDA of being responsible for the Vioxx 
controversy, criticizes the FDA’s leaders or decisions, or focuses exclusively on negative 
quotations from important political figures.  One article entitled “Common Sense: Why it is Too 
Risky to Own Big Positions in Drug Companies” highlights how the public thought that the FDA 
did a thorough vetting of drugs on the market, but that now it is clear it does not.
144  Another 
example is an article entitled “FDA Officials Tried to Tone Down Report on Vioxx” in which the 
author puts in critical quotes from critics who believe that the FDA is ignoring its own experts.
145  
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The article says that “instead of acting as a public watchdog, FDA [is] busy challenging its own 
experts.”
146  Many articles talk about the FDA being too cautious now due to Vioxx. 
  Finally, an article is negative/neutral when it brings attention to all the scrutiny of the 
FDA, but does it in an objective-fact reporting way.  For example, an article entitled 
“Cardiologist Calls for Inquiry into FDA Handling of Vioxx” reports that the FDA is facing 
questions for allowing the product to be marketed to millions.
147  The article implies that the 
FDA might play a big role in the deaths of the users.  However, it is done in a general way, 
seemingly reporting on a fact.  Another example is “Did FDA Staff Minimize Vioxx’s Red 
Flags?” where the author mentions that Congress is looking at the FDA’s role in Vioxx.
148  At 
the same time, the article does allow the FDA to defend itself.  Even so, it is not neutral because 
it follows this defense with a statement that the FDA is not aggressive enough.  The one positive 
element is surrounded with more negative quotes, making this a negative/neutral article rather 
than just neutral canceling out.   
Research Question 2: More One-Sided or Balanced 
The second research question deals with the one-sided or balanced coverage within the 
negative articles.  The Wall Street Journal has 25 articles that are negative.  Notice that this is a 
rather small number as compared to the New York Times and the Los Angeles Times.  One 
explanation might be the fact that there are many negative/neutral articles here rather than just 
negative articles.  (This discrepancy will be discussed later in the comparison section).  Out of 
those 25 articles, 16 are one-sided and 9 are more balanced.  In other words, 64% are one-sided 
and 36% are balanced.  See Figure 39 below.     
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It was hypothesized that the Wall Street Journal would be the more balanced than one-
sided because of its conservative reputation.  This is because the Wall Street Journal might try to 
support the FDA in the negative articles since that agency has an important relationship with the 
business community target newspaper audience.  However, this is not the case.  There is a 
significant discrepancy in the coverage, with more being one-sided than balanced.  What might 
be the reason for this?  Unlike the other topics where the conservative view tends to correlate 
with positive FDA coverage, here the conservative view correlates with a different type of 
negative coverage.  As such, it is not surprising to see more one-sided coverage if the 
conservative reputation is true.  In addition, the Wall Street Journal’s conservative reputation is 
more focused on the editorial section rather than on the news reporting section.   
 
An article is one-sided when it does not give the FDA a chance to defend itself after it 
includes criticism of the agency.  For example, one article entitled “Merck Downplayed Risks of 
its Vioxx” mentions that the FDA sat on all the information.
149  The article even implies that the 
FDA has been working with and helping Merck.  Another example is an article entitled “Side 
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Effects: An FDA Reviewer Battles the Drug His Boss Approved” that gives press to one critic 
who accuses the FDA of fraud and who expresses his worry about future approval.
150  The article 
does mention, however, that the FDA refused to comment for the article.
151  Even so, the author 
still could have written in some possible explanations.  Instead, the newspaper chose to take this 
refusal as an invitation to write a wholly one-sided article.   
On the other hand, a negative article is balanced when the newspaper does try to give the 
FDA a chance to defend itself amidst the negative coverage, but does not include enough lines as 
to make the article negative/neutral.  For example, an article entitled “Merck Begins its Defense 
in Second Vioxx Trial” includes many critical quotes, calling the FDA review problematic and 
saying that the public is “skeptical” of the FDA.
152  However, the article does mention that the 
FDA is aware that every drug will have some side effects, which might imply that there is a 
possible explanation.   
This one-sided/balance study also discloses some framing techniques.  This newspaper, 
unlike the New York Times and the Los Angeles Times, reports a lot about the relationship 
between Merck and the FDA, including the court cases involved.  This likely has to do with the 
newspaper’s business focus.  Another framing technique is that the articles that are neutral tend 
to have an overall condescending tone.  This causes a lot of the negative articles to seem more 
negative/neutral and might explain why there are more in the negative/neutral category than the 
other newspapers.  
Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
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  The third research question addresses editorials, looking for overall negative or positive 
coverage and specifically focusing on any potential liberal or conservative slant.  As with the 
New York Times and the Los Angeles Times, a liberal focused article argues that the agency is too 
quick to approve drugs.  A more conservatively focused article argues that the agency is now 
going to be too cautious.  Out of the 82 articles, 12 are editorials (less than 15%).  Within these 
12 articles, 3 are positive, 2 are neutral, 4 are negative, and 3 are negative/neutral.  This works 
out to be 17% neutral, 25% positive, 33% negative, and 25% negative/neutral.  See Figure 40 
below.  This is almost exactly the same as the overall breakdown coverage in the newspaper 
where 31% are negative (compared to 33% here), 24% are negative/neutral (compared to 25% 
here), 12% are positive and 5% are positive/neutral (compared to 25% here), and 17% are neutral 
(compared to 17% here).  As has become a reoccurring pattern among the newspapers, the main 
difference in the coverage is the positive and neutral categories.  The Wall Street Journal then is 
consistent overall in the amount of negative, positive or neutral coverage, not skewing more 
negative or positive in the more subjective editorial section of the newspaper.  Note that as a 
general rule, the Wall Street Journal’s editorial staff tends to be more conservative than the news 
staff, so it would not be surprising see more liberal reporting with research question 2 and 4 as 83 
compared to research question 3.  
 
The positive editorials either point blame elsewhere or explicitly make clear that the FDA  
is not at fault.  For example, one article entitled “The Painkiller Panic” argues that the public is 
overreacting to what is only a very small statistic.
153  The article implies that the FDA has done 
nothing wrong and that it is possibly the wrong decision to pull Vioxx.  The neutral editorials are 
not about the FDA exclusively and usually only mention the agency for a small fact.  An 
editorial is negative/neutral when it mentions that the FDA is in a tough position or reports on an 
FDA action, but uses the opportunity to point out the negative criticism and publicity.  For 
example, one article entitled “Merck Supports Integrity, Actions of Vioxx Witness” highlights 
how the FDA had all the information it needed from Merck at the time.
154  The clear implication 
is that the FDA is too little, too late, although the article is not direct on this front.  An article is 
negative when it blames the FDA.  Interestingly, all four negative editorials criticize the FDA, 
but do so based on the conservative viewpoint.  For example, one editorial entitled “Drug 
Twilight Zone” says that the FDA is now getting too cautious when deciding what drugs to 
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approve.
155  It mentions the “natural hyper caution of regulators.”
156  Another article entitled “A 
Vioxx Elegy” states also that the FDA has already been too cautious about drug approval and 
now any changes it makes as a result of Vioxx is going to make the situation even worse.
157  As 
such, this is a clear indication of a conservative bias in the editorials, since most editorials are 
negative in the conservative direction.   
Research Question 4: More Liberal or Conservative Leaning 
  Does the same conservative bias hold up when studying the articles overall, including the 
editorials?  Out of the 68 articles, 30 express either a liberal or conservative viewpoint.  18 of the 
articles articulate the conservative criticism that the Vioxx problem will result in the FDA 
becoming overly and unnecessarily cautious.  6 of the articles articulate a liberal criticism, 
pointing out that the agency does not effectively study the information and is too quick to 
approve drugs.  One article mentions both sides of the criticism.  This works out to be 72% 
conservative leaning, 24% liberal leaning, and 4% neutral.  See Figure 41 below. 
The conservative articles select quotes expressing the typical “too-cautious” rhetoric.  For 
example, an article entitled “Novartis Fights Eczema Drug’s Cancer Warning” shows a current 
case in which the FDA is being too cautious.
158  The article points out that FDA officials want to 
put a serious warning on a product even though the agency does not have enough concrete 
evidence yet.  Another example is an article entitled “Viable Vioxx” in which the author 
mentions that the overly-cautious attitude is the one “worrying development amid the sudden 
outbreak of FDA common sense.”
159   
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On the other hand, the liberal articles argue that the FDA is tied to Washington and that it 
is acting without considering all the evidence.  For example, one article entitled “The Bush 
Budget Proposal: FDA, FCC Get Rare Boosts” mentions how the FDA recently has received an 
increased budget due to public skepticism.
160  The article points out that people believe that the 
FDA has improperly evaluated risks in the past and needs to improve for the future.
161  Another 
example is an article entitled “Medical Journal Urges an Overhaul in FDA’s Oversight” in which 
the author explains that the FDA has started to undertake much needed reform.
162  The author 
states that this action is directly a result of criticism outside the agency that it has not handled 
safety problems properly and has often ignored or dismissed important issues too easily.
163  Only 
one article entitled “FDA Establishes Board to Review Approved Drugs” talks about both the 
conservative and liberal viewpoint.
164   It mentions that the FDA should not get too cautious, but 
at the same time, states that the agency will also need to be more cautious in the future.
165   
                                                 
160 Deborah Solomon, Anna Marie Squeo, and Anna Wilde Mathews, The Bush Budget Proposal: FDA, FCC Get 
Rare Boosts, WALL ST. J., Feb. 5, 2005. 
161 Id. 
162 Heather Won Tesoriero and Anna Wilde Mathews, Medical Journal Urges an Overhaul in FDA’s Oversight, 
WALL ST. J., Nov. 23, 2004. 
163 Id. 
164 Leila Abboud and Anna Wilde Mathews, FDA Establishes Board to Review Approved Drugs, WALL ST. J., Feb. 
16, 2005. 
165 Id. 86 
 
It was hypothesized that the conservative reputation of the newspaper comes into play 
and causes a more conservative-bias in reporting overall.  With 72% conservative as compared to 
24% liberal, this prediction has been realized here.  
2. Plan B 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
  The Wall Street Journal published 34 articles on the Plan B controversy between January 
1, 2004 and October 1, 2006.  My results are as follows: 13 articles are predominately negative, 
7 articles are negative/neutral, 10 articles are neutral, 1 article is neutral/positive, and 3 articles 
are predominantly positive.  This means that 38% of the articles are negative, 29% of the articles 
are neutral, 9% of the articles are positive, 21% of the articles are negative/neutral, and 3% of the 
articles are positive/neutral.  Figures 42 and 43 below depict these findings graphically.  The 
combined percentages are 60% negative, 29% neutral, and 11% positive.  See Figure 44 below 
for the graphical depiction.  These results are similar to Vioxx overall coverage.  For Vioxx there 
is 31% negative (compared to 38% here), 28% neutral (compared to 29% here), 12% positive 
(compared to 9% here), 21% negative/neutral (compared to 24% here), and 5% positive/neutral 87 
(compared to 3% here).  Given the small number of articles, this is astonishingly similar results.  
Like the other newspapers, the Wall Street Journal at least appears consistent in its coverage.  
However, this does not mean there is not a bias one way or the other in the newspaper as a 




An article is positive when it does not blame the FDA or accuse it of acting political.  A 
positive article might also approve of the FDA’s actions.  One article entitled “GOP Games at 
the FDA” praises the new head of the agency and then criticizes senators for pressuring the FDA 
on approving the morning after pill.
166  Another article entitled “Dr. McClellan’s Medicare Rx” 
offers implicit praise for the FDA.
167  Although the article does not directly commend the FDA, 
the author implies that he thinks the FDA made the right decision in not approving non-
prescriptive Plan B sales.  The one positive/neutral article entitled “Plan B Shift Threatens 
Deepen Rift” offers a positive, upbeat report about the ultimate FDA approval of Plan B.
168  
However, the article also mentions the past contentious battle on the issue and explains that this 
approval will inevitably pressure pharmacies across the country.
169  The small mention of 
consequences and criticisms makes the overall positive article a better fit for positive/neutral. 
An article is neutral when it is an objective factual report.  For example, an article entitled 
“Abortion Debate Shifts to New Ground” simply mentions that the FDA has not approved over 
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the counter sales of Plan B yet.
170  There is no negative inference.  In addition, an article is 
neutral when it offers both positive and negative arguments about the FDA, making it too 
subjective to decide if the article leans one way or the other.  For example, an article entitled 
“Bush to Retain FDA’s Acting Chief” mentions the politically charged battle, but does not go 
into detail about either sides’ point of view.
171      
  An article is negative when it accuses the FDA of practicing ideology and morality over 
the more proper science or it charges the FDA of being a pawn of the Administration.  Many 
articles use the phrase “lack of decision” on Plan B.  This implies that the FDA should have 
decided the issue already and has failed to do so.  For example, an article entitled “FDA Delays 
Call on Contraceptive: Split Arises Over Age Rules” mentions that the decision is “again 
delayed” and includes quotations from important figures saying “I’m very disappointed.  I 
thought we’d done everything that had been asked of us.”
172  Other articles use even harsher 
language.  For example, an editorial entitled “FDA Ombudsman Needed to Curtail Inefficiency” 
mentions that the FDA has failed to approve the drug.  The choice of the words “inefficiency” 
and “failure” make clear that this author does not approve of the FDA’s action in this matter.
173 
Finally, an article is negative/neutral when it includes mostly negative quotes, but also allows 
some positive elements.  For example, one article entitled “Bush is Set to Nominate Acting Chief 
as Head of FDA” references a number of political issues facing the FDA, including all the 
political criticisms.
174  However, the article also puts blame on the Democratic Party for the 
FDA’s plight.   
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It was hypothesized that the Wall Street Journal would have more negative coverage than 
positive coverage, namely because it is a negative issue.  In fact, the negative coverage is 
actually less than predicted with only 38%.  However, when one considers the combined results 
with the negative/neutral the number is a more predictable 60%.  Part of this discrepancy might 
be the subjective coding.  On the other hand, it is possible that the Wall Street Journal, in an 
attempt to be more objective, or perhaps demonstrating a conservative tendency to support the 
FDA, actually reports more objectively within the negative coverage.  Perhaps that is why it has 
more negative/neutrals and less negatives overall.  Like the other two newspapers, the Wall 
Street Journal also appears to be slightly more negative on the Plan B issue than the Vioxx issue 
where only 55% are negative.  This is surprising since the Vioxx conservative issues are also 
negative whereas here the Plan B conservative issues are positive. 
Research Question 2: More One-Sided or Balanced 
The second research question studies the negative articles for balance.  The Wall Street 
Journal publishes only 13 articles that are predominately negative.  Out of those 13, 7 are one-
sided and 6 are balanced.  This works out to be an almost even split with 46% balanced and 54% 
one-sided.  See Figure 45 below.  These results are very different than the Vioxx results where 
the breakdown skewed significantly towards the one-sided category with 64%.  As with both the 
New York Times and the Los Angeles Times, one possible reason for this difference is due to the 
more clearly defined liberal and conservative positions for this category (science vs. 
promiscuity).  A newspaper with a conservative reputation might be expected to include the 
more conservative elements in the negative articles.  For Plan B, this means more positive 
coverage.  As such, it makes sense that the Wall Street Journal might have a more even split here 
as compared to Vioxx in which even the conservative viewpoint is negative for the FDA.   91 
 
The one-sided articles highlight the FDA’s handling of the controversy or point out the 
delay.  For example, an article entitled “Probe Concludes Acting FDA Chief Didn’t Have Affair” 
talks about the FDA’s failure to act without any positive defenses or explanations.
175  Another 
example is an article entitled “Senate Clears Spending Bills, Farm, Military Benefits” in which 
the author criticizes the agency for taking too long to decide on the issue due to political 
pressure.  It explains that people are “deeply disappointed with the continued delays.”
176   
The more balanced articles give the FDA a chance to explain its side or, alternatively, 
reference conservative values that tend to support the delayed decision, such as the important 
sexual consequences for teenagers.  For example, one article entitled “Bush Faces Challenge 
From Scientists” reports that a liberal group is criticizing the agency.
177  Although a negative 
article, the use of the “liberal group” term is most likely included so that the reader understands 
who is actually making the argument.  The liberal label is placed in an obvious separate sentence 
so that the reader cannot overlook it.  In fact, like with the New York Times, the Wall Street 
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Journal consistently used this framing technique, placing quotations rather than its own analysis 
to appear more objective.  Yet the Wall Street Journal is still choosing which quotes to include.  
Another example is “FDA Restricts Morning After Pill” in which the majority of the article is 
critical of the decision and talks about how many believe politics are to blame.
178  However, the 
article does offer a voice for the FDA by pointing out that the FDA believes that the evidence 
was unsupported.
179  
Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
  The third research question addresses the issues through an editorial study, with a specific 
focus on Wall Street Journal’s liberal/conservative tendencies.  Out of the 34 articles, 4 are 
editorials or 12% (as compared to 15% for Vioxx).  Within these 4 articles, 1 is positive, 1 is 
negative/neutral, and 2 are negative.  This works out to be 0% neutral, 25% positive, 25% 
negative/neutral and 50% negative.  See Figure 46 below.  The numbers are similar, but not 
exactly aligned to the overall Plan B coverage since there is a little less positive coverage, 
replaced with slightly more negative editorial coverage.  Here 50% are negative as compared to 
38% overall for Plan B coverage.  Notice that here 75% combined are negative whereas overall 
only 60% are negative.  This is a rather significant difference.  The editorials on the Plan B 
subject tend to be more negative than the overall coverage on Plan B and throw off the 
consistency seen with Vioxx.  This is surprising since the conservative viewpoint is positive 
towards the FDA and easily lends itself to editorial coverage.  However, one explanation for this 
discrepancy might be the small number of articles so that it is unwise to make any real 
conservative or liberal conclusions.     
                                                 
178 Leila Abboud, FDA Restricts Morning After Pill, WALL ST. J., May. 7, 2004. 
179 Id. 93 
 
An editorial is negative when it calls the FDA decision-making delay a failure.  The one 
negative/neutral editorial entitled “Advise and Consign” talks about Senator Clinton and her 
complaints about the agency, but does not actually support her opinion.
180  However, the 
introduction of her negative quotes such as the “agency is stalling” makes this more 
negative/neutral than neutral.  The one positive editorial entitled “GOP Games at the FDA” 
(mentioned previously) praises the new head of the FDA and criticizes political figures for 
pressuring the FDA to approve the drug.
181    
Below is a brief comparison to Vioxx (although one should keep in mind the small 
numbers).  Plan B seems to have much more negative editorials with 50% negative as compared 
to 33% for Vioxx.  This is especially true since the negative/neutral and the positive for both 
Plan B and Vioxx are equivalent.  The one difference is in the neutral category, where here none 
are neutral as compared to Vioxx which has an extra 17% neutral.  
Research Question 4: More Liberal or Conservative Leaning 
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   Lastly, the study focuses on the articles as a whole to see if there is a liberal or 
conservative bias.  With a larger number of articles, the results should be more significant.  Out 
of the 34 articles, only 4 articles mention the conservative viewpoint, such as the sexual 
implications of the drug.  9 articles mention the liberal viewpoint, most pointing out that the 
FDA is giving in to political pressure or delaying a decision inappropriately.  One article 
mentions both the liberal and conservative viewpoint.  This means that 64% of the articles 
express a liberal viewpoint, 7% of the articles express both viewpoints, and 29% of the articles 
express a conservative viewpoint.  See Figure 47 below.  Besides for previous examples, another 
liberal article entitled “FDA Moves Toward Approving Over the Counter Plan B Sales” allows 
the author to report on recent resignations at the FDA for what the quitters say is decision-
making not based on science.
182  The more conservative articles praise the FDA for considering 
all the potential family and teenage problems with approving the drug.  The one article that 
mentions both viewpoints entitled “FDA’s Delay Over Contraceptive Prompts Resignation of 
Official” offers criticism by including a quote saying “I really feel like this decision was not 
based on science and clinical evidence.”
183  However, the article also gives the FDA a chance to 
defend itself, articulating this is not a political decision, but based on numerous factors that must 
be considered when approving a drug.
184   
It was hypothesized that there would be a more conservative bias over a more liberal bias.  
This does not appear to be the case here.  This is interesting since there is a clearly defined 
conservative and liberal position, making it easier for a newspaper with a conservative slant to 
write conservative stories.  However, perhaps this can be explained through comparison.  The 
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Vioxx coverage is a more conservative 72% and liberal 24% (as compared to 29/64 here).  One 
explanation for the high percentage of liberal coverage might be the negative story.  Since the 
liberal viewpoint is negative and the conservative viewpoint is positive, it makes sense that 
negative reporting lends itself to liberal arguments.  This is different than Vioxx where the 
negative story also lends itself to conservative arguments.  Another potential reason is the small 
number of articles, making these numbers suspect to any real analysis.  Finally, of course, the 
liberal tendency might mean that the Wall Street Journal’s reputation for conservative reporting 
is untrue here.  Another potential explanation is that, as a general matter, the news reporting staff 
tends to be more liberal than the editorial staff.  
 
3. Ephedra 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The Wall Street Journal only published 14 articles on the Ephedra controversy between 
January 1, 2002 and January 1, 2004.  This has become a reoccurring pattern among all the 
newspapers.  Clearly, the Ephedra story is not nearly as reported on overall when compared to 
Vioxx or Plan B.  My results are as follows: 1 article is predominately negative, 2 articles are 96 
negative/neutral, 5 articles are completely neutral, 5 articles are neutral/positive, and 1 article is 
predominantly positive.  This means that 7% of the articles are negative, 36% of the articles are 
neutral, 7% of the articles are positive, 14% of the articles are negative/neutral, and 36% of the 
articles are positive/neutral.  Figures 48 and 49 below depict these findings graphically.  The 
combined results are 21% negative, 36% neutral, and 43% positive.  See Figure 50 below for the 




It was hypothesized that the Wall Street Journal would have more neutral articles on this 
topic rather than negative articles since the topic can be viewed more positively towards the 
FDA.   Yet, based on Figure 50, this is slightly incorrect, but in a surprising direction.  Contrary 
to the previous Vioxx and Plan B examples, the Wall Street Journal actually has more positive 
coverage overall as compared to negative and neutral coverage.  This difference might be a due 
to the topic or perhaps it is indicative of a business community that supported the Ephedra ban 
since Ephedra put a damper on the entire dietary supplement industry.  Thus, is it not surprising 
that the Wall Street Journal would praise the FDA for its more robust efforts in this time period 
as being in line with the interests of that industry. 
The one positive article entitled “Ephedra Marketer Comes Under New Criticism” praises 
the FDA, stating that it is “cracking down” on Ephedra.  This implies that the FDA is a strong 
agency that is on top of its duties.
185  Similarly, an article is positive/neutral when it speaks 
positively about the FDA’s role in the Ephedra regulation, but arguably reports it in a neutral 
way.  For example, an article entitled “FDA is Expected to Ban Ephedra, Citing Supplement’s 
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Health Risks” mentions that the FDA “struggled” with this issue and engaged in “years of 
debate.”
186  At the same time, the article makes clear that the FDA is doing what it can within the 
laws.
187  Another example is an article entitled “Winter Olympic 2002: The Olympics Doc Takes 
on a Hometown Power” in which the author mentions the ongoing debate and complains that the 
regulations need to be changed.
188  The article offers no FDA criticism and even says that many 
will support the FDA in using its powers to deal with Ephedra.
189   
An article is neutral when it only reports on the facts, like the FDA’s role or any future 
steps.  For example, an article entitled “Young Athletes: Play it Safe in Sun: Laying off 
Videogames, Nixing High Protein Foods Helps Prevent Heat Illness” mentions the FDA only 
briefly to report that the agency says that Ephedra has negative side effects.
190  A neutral article 
might also have both positive and negative reporting.  For example, an article entitled “FDA 
Seeks Side-Effects Reports on Dietary Supplements, Foods” points out that the FDA has many 
critics.
191  Yet, the article is also positive, emphasizing that the FDA is seeking to provide 
consumers with information.  The author reports that many are “applaud[ing] the FDA for 
moving in the direction of national mandatory reporting system.”
192 
  The predominately negative article accuses the FDA of not confronting the issue.  The 
article entitled “Herbal Overdose” says that the FDA has “stopped short” of fulfilling its charge 
to assure that health products are both safe and effective.”
193  The two negative/neutral articles 
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just report the facts, although managing to include some negative comments.  For example, an 
article entitled “GNC to Card for Supplements” condescendingly says that the FDA does not 
require warning labels or ID checks.
194  It is more neutral though because the statement is 
included to explain why GNC is choosing to do this itself, and is not necessarily meant to 
criticize the FDA.  The other example entitled “FDA Proposes Rules for Dietary Supplements” 
praises the FDA for implementing general guidelines, but the article spends a significant amount 
of space referencing disappointment in the agency.
195  It says that the FDA has “finally” acted.
196  
Thus, even with the original praise, the author writes the article in an overall negative way, 
highlighting criticisms.   
Research Question 2: More One-Sided or Balanced 
The second research question discusses the balance in the negative articles.  
Unfortunately, this study does not work well for Ephedra since there is only 1 negative article.  
To get some results, one might use the 2 negative/neutral articles also.  Yet, this does not really 
improve the results much, since it only adds 2 additional articles.  Since the statistics are really 
valueless with such small numbers, it is unproductive to compare these results to Vioxx and Plan 
B coverage.  Out of those 3 articles, 2 are one-sided and only 1 is balanced.  The more balanced 
article is the last one discussed in the negative/neutral section.  The GNC article above is one of 
the one-sided articles, although it is also slightly neutral.  As such, including the GNC article 
when it is the most unreliable based on my reliability test might skew the results too much.  
Therefore, it might be wise to disregard this article in the results also.  Using the two articles left, 
there is an even 50/50 split.  See Figure 51 below.   
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Research Question 3 and 4: More Negative, Neutral, or Positive Editorial Coverage/More Liberal 
or Conservative Leaning   
The third research question addresses the editorials to discover issue-content and any 
liberal and conservative bias.  However, none of the 14 articles are editorials.  This forces me to 
skip question 3 and move to question 4 which addresses overall liberal and conservative 
coverage.  For Ephedra, the liberal/conservative positions are less clear.  A liberal article 
criticizes the FDA for making decisions based on politics.  A conservative article commends the 
FDA for its thought out approach or supports the FDA as a part of the Administration.  After 
coding the articles for this subject, none of the articles clearly represent either viewpoint.  As a 
result, there is not enough information to decide if the Wall Street Journal is liberal or 
conservative on the Ephedra issue.  This is not surprising since the other newspapers also found 
weak results.  
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VII. Analysis Comparing the Three Newspapers 
  This part of the study quantitatively compares the different newspapers, organized by 
topic.  It offers possible explanations for the results and compares the findings to the original 
hypothesis.  It compares the newspapers based on the same four research questions, asking 
whether the newspapers: (1) publish more negative, positive, or neutral articles about the FDA, 
(2) publish more balanced or one-sided articles about the FDA, (3) publish more negative, 




Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The New York Times percentage breakdown is 44% of the articles are negative, 19% of 
the articles are neutral, 13% of the articles are positive, 18% of the articles are negative/neutral, 
and less than 6% of the articles are positive/neutral.  The combined breakdown is 62% negative, 
19% neutral, and 19% positive.  In comparison, the Los Angeles Times percentage breakdown is 
60% of the articles are negative, 21% of the articles are neutral, 12% of the articles are positive, 
7% of the articles are negative/neutral, and none of the articles are positive/neutral.  The 
combined breakdown is 67% negative, 21% neutral, and 12% positive.  On the other hand, the 
Wall Street Journal percentage breakdown is 31% of the articles are negative, 28% of the articles 
are neutral, 12% of the articles are positive, 24% of the articles are negative/neutral, and 5% of 
the articles are positive/neutral.  The combined breakdown is 55% negative, 28% neutral, and 
17% positive.  See Comparison Figures 1 and 2 below for the graphical comparisons. 102 
 
   
As these figures demonstrate, there are some clear differences among the newspapers.  For 
example, the Wall Street Journal tends to have less negative articles than the other newspapers: 
60% of the Los Angeles Times articles are negative as compared to only 44% for the New York 
Times and 31% for the Wall Street Journal.  However, the Wall Street Journal makes up for this 
lower number in negative/neutral coverage, with the most negative/neutral coverage of all the 
newspapers at 24% as compared to the Los Angeles Times at 7% and the New York Times at 
18%.  Thus, even though the Wall Street Journal appears to be less negative based on 103 
Comparison Figure 1, when one combines negative/neutral and negative, the numbers are less 
skewed.  Yet, even there the Wall Street Journal is on the lower side with only 55% of the 
articles overall being negative as compared to 67% for the Los Angeles Times and 63% for the 
New York Times.    
Interestingly, this does not mean that the Wall Street Journal publishes more positive 
coverage.  On the other hand, the positive coverage between the papers is very close at 17%, 
21%, and 19%.  The bigger discrepancy is in the neutral coverage where the Wall Street Journal 
has 28% neutral as compared to the Los Angeles Times at 12% and the New York Times at 19%.  
Overall, the Los Angeles Times tends to report the most negatively about Vioxx with the New 
York Times falling closely in the middle.   
  It was hypothesized that the Los Angeles Times would have the most negative coverage, 
followed next by the New York Times and finally the Wall Street Journal.  Based on these 
results, the predictions are correct.  One possible reason is that the liberal tendency of the former 
two newspapers results in a higher degree of negative commentary over neutral commentary as 
compared to the more conservative newspaper.  However, recall that Vioxx conservative 
viewpoints are also negative.  Thus, this hypothesis makes less sense for the Wall Street Journal 
where one would arguably expect to still see negative coverage overall.  Perhaps this explains 
why the Wall Street Journal has more negative/neutral articles rather than just negative.  The 
newspaper is possibly struggling between wanting to support the FDA, which might be perceived 
as important to its core audience, and wanting to represent the conservative and liberal 
viewpoints.   
Note also how close these numbers really are between the newspapers.  There is very 
little difference when one combines the negatives with the negative/neutral between the 104 
newspapers.  As a result, it is equally plausible that there is really no pattern at all and that none 
of the newspapers demonstrate any bias or negativity towards the FDA or a particular ideological 
group.  
Research Question 2: More One-Sided or Balanced Overall 
The New York Times has a pretty even split with 53% one-sided as compared to 47% 
balanced.  The Los Angeles Times has a more divergent split with 37% one-sided as compared to 
63% balanced.  The Wall Street Journal is on the opposite end of the spectrum as compared to 
the previous newspaper with 64% one-sided as compared to 36% balanced. See Comparison 
Figure 3 below.    
 
 As one can see by this graph, there is an obvious difference between the newspapers, with a 
wide spectrum in each category.  The Los Angeles Times, the newspaper with the most negative 
coverage overall, actually is the most balanced within the articles, followed by the New York 
Times.  This is contrary to the hypothesis.  It was predicted that the Los Angeles Times, with the 
strongest liberal reputation, would be more likely to include only negative coverage about the 
FDA and not give it a chance to defend itself or explain both sides.  On the other hand, it was 105 
also predicted that the Wall Street Journal would be the most objective, yet it ended up being the 
most subjective.   
Perhaps the fact that there are conservative criticisms as well as liberal criticisms makes it 
easier for the Wall Street Journal to be one-sided in the article.  Thus, any support the Wall 
Street Journal might have for the FDA has to be balanced against the negative story and the 
conservative groups that are upset with the FDA.  Given the negative conservative viewpoints, it 
is not counterintuitive that the Wall Street Journal might be the most one-sided coverage.  It 
should be interesting to see if this result remains in the later parts when the conservative 
coverage is more positive.    
Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 
The New York Times editorial breakdown is 31% neutral, 8% positive, and 61% negative.  
The Los Angeles Times editorial breakdown is 20% neutral, 13% positive, and 67% negative.  
Finally, the Wall Street Journal editorial breakdown is 17% neutral, 25% positive, 33% negative, 
and 25% negative/neutral.  See Comparison Figure 4 below.  Editorials are an editor’s one 
opportunity to publish and choose subjective articles.  Thus, it is one of the clearest indications 
of whether the newspaper tends to represent the FDA in a positive, neutral, or negative way. 
It was hypothesized that the Los Angeles Times would be the most negative in editorial 
coverage, followed by the New York Times and the Wall Street Journal.  This appears to be the 
case: the newspapers with the more liberal reputations have the most negative commentary and 
the newspaper with the more conservative reputation has the most positive coverage.  However, 
again, the Wall Street Journal has the outlier negative/neutral category that can skew these 
results.   106 
 
Research Question 4: More Liberal or Conservative Leaning 
For Vioxx, liberal reporting focuses on the “too quick to approve” reputation of the FDA.  
Conservative reporting focuses on the “too cautious” rhetoric, worrying that the FDA will now 
not approve drugs as quickly.  The New York Times liberal/conservative split is 56% liberal, 38% 
conservative, and 6% both.  The Los Angeles Times liberal/conservative split is 64% liberal, 29% 
conservative, and 7% both.  The Wall Street Journal liberal/conservative split is 24% liberal, 
72% conservative, and 4% both.  See Comparison Figure 5 below. 
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It was hypothesized that the overall criticism by the Wall Street Journal would be 
predominately conservative as compared to the Los Angeles Times which would be the most 
liberal.  In addition, the New York Times should fall somewhere in the middle, but be closer to 
the Los Angeles Times because it has a similar liberal reputation.  This is exactly correct.  In fact, 
the Wall Street Journal had a whopping 72% conservative coverage as compared to only 24% 
for the liberal coverage.  On the other hand, the Los Angeles Times comes out ahead in liberal 
articles, but it is followed closely behind by the New York Times.  In fact, the Wall Street Journal 
and the Los Angeles Times are almost mirror images of each other.  It is quite interesting that the 
newspaper with the more conservative reputation reports more frequently on the conservative 
criticism and the newspaper with the more liberal reputation reports just as frequently on the 
liberal criticism.   
B. Plan B 
Research Question 1: More Negative, Positive, or Neutral Articles Overall 
The New York Times percentage breakdown is 60% of the articles are negative, 15% of 
the articles are neutral, 7% of the articles are positive, 16% of the articles are negative/neutral, 
and less than 2% of the articles are positive/neutral.  The combined breakdown is 77% negative, 
15% neutral, and 8% positive.  In comparison, the Los Angeles Times percentage breakdown is 
56% of the articles are negative, 12% of the articles are neutral, 10% of the articles are positive, 
20% of the articles are negative/neutral, and 2% of the articles are positive/neutral.  The 
combined breakdown is 71% negative, 18% neutral, and 11% positive.  On the other hand, the 
Wall Street Journal percentage breakdown is 38% of the articles are negative, 29% of the articles 
are neutral, 9% of the articles are positive, 21% of the articles are negative/neutral, and 3% of the 108 
articles are positive/neutral.  The combined breakdown is 60% negative, 29% neutral, and 11% 
positive.  See Comparison Figures 6 and 7 below. 
 
   
Unlike with Vioxx, the papers are much closer together in Plan B coverage, although some 
noticeable differences exist.  As Comparison Figure 6 depicts, the Wall Street Journal again has 
the least negative and the most neutral coverage as compared to the other two newspapers 
negative coverage.  The Wall Street Journal has only 38% negative as compared to the New York 
Times at 60% in the predominately negative category and the Los Angeles Times with 56% in 109 
that same category.  Unlike with Vioxx, the negative-neutral category is more closely aligned 
between the newspapers.  There is a similar pattern where the Wall Street Journal moves away 
from the other papers in the neutral coverage.   
This might indicate some type of framing technique of the Wall Street Journal.  After all, 
the newspaper is choosing to report articles in a noticeably more neutral way than its 
competitors.  Perhaps this is due to the conservative desire to not criticize the FDA if the author 
unintentionally or explicitly thinks this is criticizing the Republican Party or harming the 
business community.  However, an equally plausible reason is that the Wall Street Journal is a 
more objective newspaper.   
Comparison Figure 7 depicts the comparison of the combination numbers.  The New York 
Times has the most negative coverage followed by the Los Angeles Times.  Consequently, the 
New York Times has the least neutral coverage again followed by the Los Angeles Times.  The 
Wall Street Journal has the most neutral and least negative coverage.  The Los Angeles Times 
has the most positive coverage rather than the Wall Street Journal, albeit it is a very close 
second.    
  Like with Vioxx, it was predicted that the Los Angeles Times would have the most 
negative and least positive coverage, followed by the New York Times, and then finally the Wall 
Street Journal.  Related, the Wall Street Journal should have the most positive coverage.  Based 
on the results, this does not appear to be the case.  In fact, surprisingly, the Los Angeles Times 
tied the Wall Street Journal in positive coverage and is significantly higher than the New York 
Times (11% compared to 2%).  That the New York Times has the most negative and least positive 
coverage is not completely shocking.  Perhaps the Plan B issue is more prominent in the New 
York region.  Also, the negative difference between the two liberal-reputed papers is small (77% 110 
for the New York Times and 71% for the Los Angeles Times).  In fact, the close results and the 
clear difference from the Vioxx results (specifically the Los Angeles Times positive coverage) 
might indicate that there is no real pattern.  In other words, perhaps there is no liberal or 
conservative bias and the newspapers do not portray the FDA unfairly negatively if the story is 
also negative.   
Research Question 2: More One-Sided or Balanced Overall 
This section compares one-sided and balanced coverage of the three newspapers.  The 
New York Times has a pretty even split with 70% one-sided as compared to 30% balanced.  The 
Los Angeles Times has an identical split with 70% one-sided as compared to 30% balanced.  The 
Wall Street Journal is different 54% one-sided as compared to 46% balanced.  See Comparison 
Figure 8 below. 
 
It was hypothesized that the New York Times and the Los Angeles Times, the newspapers 
with the liberal reputations, would be most likely to criticize the FDA when the government is 
run by the more conservative party or just generally focus on more liberal values and decline to 
include any positive conservative coverage or real praise for the FDA.  As predicted, both 111 
newspapers have a significantly higher amount of one-sided coverage rather than balanced 
coverage.  Of course, this does not mean that there is necessarily a liberal bias or a vendetta 
against the FDA.  The newspapers might have simply felt that all that is worth reporting on for 
most articles is the negative aspect.  Given that the newspapers are reporting similarly, this might 
indicate more of an industry practice than a newspaper bias. 
However, when one compares this to the Wall Street Journal, there is a discrepancy that 
cannot be ignored.  That newspaper has an almost even split between one-sided and balanced 
coverage.  This might indicate that the New York Times and the Los Angeles Times do paint the 
FDA more negatively than the more objective and fair Wall Street Journal.  Yet, equally 
plausible is that the Wall Street Journal, the outlier newspaper here, is actually the one with the 
conservative bias and the other two newspapers are more objective.  The article might appear to 
be more balanced when the conservative viewpoint is included (unlike Vioxx where this should 
still keep the article negative and one-sided).  The Wall Street Journal might be more likely to 
praise the FDA when it is unwarranted or report the positive conservative viewpoint in an 
attempt to represent the conservative side and not for the sake of balance or objectivity.  This 
might also explain the difference with Vioxx where the Los Angeles Times has the most balanced 
coverage and the Wall Street Journal has the most one-sided coverage.   
  Like with the Plan B breakdown above, one part of the hypothesis did fail here.  It was 
predicted that the Los Angeles Times would have slightly higher one-sided coverage than the 
New York Times.  Yet, as with Research Question 1, this is not surprising since the New York 
Times and the Los Angeles Times are arguably equal since both have an alleged liberal bias.  
 Research Question 3: More Negative, Neutral, or Positive Editorial Coverage 112 
The New York Times editorial breakdown is 85% negative, 10% positive, and 5% neutral.  
The Los Angeles Times editorial breakdown is 67% negative, 25% positive, and 8% neutral. 
Finally, the Wall Street Journal editorial breakdown is 50% negative, 25% positive, 0% neutral 
and 25% negative/neutral.  See Comparison Figure 9 below.  These numbers show a similar 
pattern with the New York Times at the highest negative coverage and the lowest positive 
coverage and the Wall Street Journal at the highest positive coverage (tied with the Los Angeles 
Times) and the lowest negative coverage.  Yet, once again, there is that same negative/neutral 
category that distorts the results and allows the Wall Street Journal to make up for the lower 
negative coverage.  This might be an indication of a more objective newspaper who tries to 
represent a more neutral negative article.  On the other hand, it might be a framing technique or, 
alternatively, it might represent a propensity to not criticize the FDA due to a respect for the 
current government or to please the readers.   
 
Research Question 4: More Liberal or Conservative Leaning 
The last research question addresses the liberal or conservative tendencies of the 
newspapers based on my labeling of liberal/conservative values.  Liberal reporting is when an 113 
article accuses the FDA of being beholden to the Administration or governing based on ideology 
rather than science.  Conservative reporting is when an article focuses on so-called “family” 
values such as the risk to children if the over-the-counter morning after pill is approved.  The 
New York Times liberal/conservative split is 78% liberal, 11% conservative, and 11% both.  The 
Los Angeles Times liberal/conservative split is 70% liberal, 25% conservative, and 5% both.  The 
Wall Street Journal liberal/conservative split is 64% liberal, 29% conservative, and 7% both.  
See Comparison Figure 10 below.  
 
Like with Vioxx, it was hypothesized that the Wall Street Journal would have more 
articles articulating conservative values whereas the Los Angeles Times and the New York Times 
would be more liberal focused.  As one can see, based purely on a comparison, the Wall Street 
Journal does have the most conservative coverage.  Even though it still has more liberal 
coverage overall, the lower numbers for the liberal coverage and the higher numbers for the 
conservative coverage might suggest a conservative-leaning agenda.  At the same time, the 
breakdown between liberal and conservative coverage in the Wall Street Journal is much closer 114 
together than for the other two newspapers, so perhaps it is actually more objective than the other 
newspapers.  After all, the New York Times has the most liberal articles.  
 It is hard to explain away the differences between the New York Times and the Los 
Angeles Times.  Perhaps the Los Angeles Times is more objective than the New York Times.  On 
the other hand, perhaps if the study included a much higher number of articles and topics, these 
small differences might melt away.  As such, it is also possible that these results show a similar 
reporting technique among all the newspapers and that there really is no pattern or any particular 
feeling towards the FDA.    
C. Ephedra 
Research Question 1: More negative, positive, or neutral articles overall 
The New York Times percentage breakdown is 17% of the articles are negative, 43% of 
the articles are neutral, 11% of the articles are positive, 6% of the articles are negative/neutral, 
and less than 23% of the articles are positive/neutral.  The combined breakdown is 23% negative, 
43% neutral, and 34% positive.  In comparison, the Los Angeles Times percentage breakdown is 
15% of the articles are negative, 49% of the articles are neutral, 18% of the articles are positive, 
15% of the articles are negative/neutral, and 3% of the articles are positive/neutral.  The 
combined breakdown is 30% negative, 49% neutral, and 21% positive.  On the other hand, the 
Wall Street Journal percentage breakdown is 7% of the articles are negative, 36% of the articles 
are neutral, 7% of the articles are positive, 14% of the articles are negative/neutral, and 36% of 
the articles are positive/neutral.  The combined breakdown is 21% negative, 36% neutral, and 
43% positive.  See Comparison Figures 11 and 12 below. 115 
 
 
Interestingly, the coverage breakdown here is very different than Vioxx and Plan B.  All 
three newspapers have less negative coverage than another category.  This difference is most 
likely due to the topic difference since Ephedra is the most positive story for the FDA out of all 
of the topics.  For the New York Times and the Los Angeles Times the highest percentage is the 
neutral category.  On the other hand, for the Wall Street Journal, the highest percentage is the 
positive category.   116 
It was hypothesized that the Los Angeles Times is the most negative, followed by the New 
York Times, and finally the Wall Street Journal.  Here the predictions are correct.  Unlike the 
previous example, the Los Angeles Times now has the more negative coverage as compared to 
the New York Times.  Since the two liberal newspapers are again switching places, this further 
supports the argument that over the long run these differences might even out and these two 
newspapers might have very similar results.  This might indicate a mutual bias, or, on the other 
hand, an objective reporting style of both newspapers.   
The more interesting results are the comparisons with the Wall Street Journal.  Once 
again, there is a difference between the two newspapers with the liberal reputation as against the 
one newspaper with the conservative reputation.  The former two newspapers are less inclined to 
praise the FDA and prefer to use a more objective reporting style.  The more conservative 
newspaper has a significantly higher number of positive articles than the Los Angeles Times and 
to a lesser extent, the New York Times.  The same pattern also reappears in which the Wall Street 
Journal makes the positive or negative articles more neutral.   
Perhaps the Wall Street Journal is more objective overall or more likely to support the 
FDA as compared to the other two newspapers due to the overwhelming support in the business 
community for a ban on Ephedra.  On the other hand, perhaps its outlier position to the other two 
newspapers indicates that it is actually the more biased one, trying to report positively on an 
issue that should receive more neutral reporting due to the time-lapse on the issue at the FDA.   
Research Question 2: More One-sided or Balanced Overall 
This section looks at the negative articles to determine one-sided or balanced coverage.  
The New York Times has a noticeable split with 67% one-sided as compared to 33% balanced.  
The Los Angeles Times, however, has a massive split with 80% one-sided as compared to 20% 117 
balanced.  On the other hand, the Wall Street Journal has the most even coverage thus far with 
an even 50/50 split.  See Comparison Figure 13 below. 
 
 This is very similar to the Plan B results, but, at the same time, it is different than the 
Vioxx results.  The New York Times and the Los Angeles Times both have more articles that are 
less balanced than the Wall Street Journal.  In fact, the Wall Street Journal has a perfect 50/50 
split.  This supports the hypothesis that the more liberal newspapers, the Los Angeles Times and 
the New York Times, tend to be more critical and one-sided in the negative articles whether due 
to an antagonism to the current government or some undiscovered reason as compared to the 
more conservative newspaper, the Wall Street Journal.  Yet, recall that the 50/50 result for the 
Wall Street Journal are really unusable since it is based on only two articles.  As such, the better 
comparison is between the two other newspapers exclusively.    
It was predicted that the Los Angeles Times is the most biased of the two liberal 
newspapers.  This is what has occurred here.  This is different than Plan B where the New York 
Times has more negative coverage than the Los Angeles Times.  Once again, the two newspapers 118 
might just be so similar in reporting styles that it makes sense for them to switch off in these 
categories within small margins of each other.   
Research Questions 3 and 4: More Negative, Positive, or Neutral Editorial Coverage/ Liberal or  
Conservative Leaning 
The editorial section and the liberal conservative sections are combined since there are 
few results and they share similar patterns.  Most importantly, the Wall Street Journal is not 
included in either comparison since there are no editorials and none of the 15 articles indicate 
political bias.  Similarly, the New York Times cannot be included in question 3 since only one 
editorial is published.  Thus, the editorial comparison and question 3 cannot be addressed here.   
As for research question 4, the results are not perfect.  Both the Los Angeles Times and 
the New York Times have a very small number of articles so that it is troubling to make any 
general conclusions or observations from these results.  As such, below is the graph comparing 
the New York Times and the Los Angeles Times for the liberal/conservative bias study only, but 
this section refrains from making sweeping predictions.  The New York Times 
liberal/conservative split is 42% liberal, 50% conservative, and 8% both.  The Los Angeles Times 
liberal/conservative split is 50% liberal, 50% conservative, and 0% both.  See Comparison 
Figure 14 below.  These results are almost equivalent, since the only reason the New York Times 
has the lower liberal number is due to articles that use both, and, more importantly, not due to 
more conservative articles.  Notice that both newspapers have a high amount of conservative 
articles and the New York Times even has a majority of conservative articles.  Perhaps this is due 
to the poorly-defined liberal and conservative viewpoints for Ephedra.   Furthermore, perhaps the 
newspapers are objective, including more positive coverage (which might be conservative here 




  This study only begins to touch on the very difficult issue of newspaper framing, 
especially when related to neutral government agencies as opposed to interest groups and 
politics.  It would be informative to see if these results are repeated on a larger scale with a 
variety of different agencies.  Interestingly, within the New York Times and the Los Angeles 
Times coverage, the newspapers both tend to be more negative and liberal overall.  On the other 
hand, the Wall Street Journal tends to have more neutral articles and a less clearly defined liberal 
or conservative split among the topics (as sometimes there is more liberal than conservative).  
However, when one compares the newspapers together, it does appear that the Wall Street 
Journal is more likely to report positively on the FDA or represent conservative values as 
compared to the other two newspapers.  Within the New York Times and the Los Angeles Times, 
there is a reoccurring shift in terms of overall negativity.  This might mean that they are similar 
and therefore actually objective.  On the other hand, these results might represent a framing and 
reporting technique of more liberal newspapers.  